{"index": [409, 270, 407, 127, 51, 50, 397, 49, 403, 258, 387, 363, 48, 71, 405, 381, 7, 69, 56, 47, 121, 62, 265, 55, 63, 264, 401, 46, 261, 61, 64, 37, 414, 2, 367, 0, 54, 41, 395, 45, 150, 260, 35, 40, 386, 28, 34, 22, 266, 149, 135, 380, 384, 32, 17, 44, 103, 26, 58, 68, 268, 57, 66, 139, 65, 373, 38, 1, 393, 370, 8, 20, 53, 375, 70, 394, 59, 457, 365, 271, 115, 376, 67, 374, 43, 42, 27, 98, 5, 13, 60, 92, 93, 433, 293, 424, 36, 19, 126, 6, 389, 18, 422, 10, 369, 33, 257, 24, 110, 122, 364, 52, 385, 296, 9, 30, 15, 131, 398, 3, 156, 160, 12, 372, 102, 267, 31, 136, 11, 294, 263, 114, 73, 165, 204, 25, 124, 235, 233, 16, 23, 170, 201, 95, 423, 133, 390, 211, 232, 128, 125, 205, 221, 234, 300, 231, 21, 112, 99, 172, 175, 14, 168, 177, 227, 208, 216, 230, 236, 97, 360, 179, 259, 123, 242, 425, 163, 382, 113, 181, 226, 416, 118, 399, 209, 159, 167, 224, 130, 173, 297, 301, 100, 171, 162, 237, 421, 174, 4, 228, 214, 207, 239, 311, 251, 169, 206, 482, 412, 219, 200, 225, 303, 182, 223, 304, 222, 306, 213, 197, 29, 72, 411, 246, 96, 329, 119, 305, 400, 241, 326, 178, 391, 252, 273, 210, 229, 188, 185, 377, 193, 346, 215, 345, 350, 147, 186, 272, 356, 313, 396, 220, 199, 379, 187, 245, 274, 248, 269, 129, 298, 247, 189, 314, 192, 335, 420, 383, 253, 353, 94, 281, 191, 218, 212, 337, 322, 406, 134, 276, 368, 336, 196, 280, 278, 120, 195, 217, 198, 117, 307, 87, 176, 289, 166, 238, 249, 317, 183, 104, 250, 299, 418, 330, 341, 254, 319, 146, 161, 351, 340, 203, 361, 89, 108, 410, 180, 352, 342, 83, 332, 327, 277, 338, 164, 318, 321, 202, 80, 358, 302, 194, 359, 106, 39, 184, 316, 244, 243, 111, 366, 284, 331, 90, 290, 320, 408, 78, 109, 417, 343, 285, 309, 190, 291, 440, 74, 413, 404, 292, 286, 325, 81, 362, 275, 279, 312, 315, 101, 240, 77, 347, 328, 419, 355, 378, 349, 116, 85, 310, 339, 84, 262, 354, 283, 308, 287, 105, 107, 76, 348, 132, 141, 333, 75, 357, 324, 157, 388, 334, 323, 288, 155, 344, 86, 91, 371, 148, 144, 142, 151, 145, 82, 153, 158, 137, 392, 88, 143, 79, 415, 282, 402, 138, 295, 256, 255, 152, 154, 140], "aeid": [2363, 804, 2127, 103, 2093, 2091, 2057, 2089, 2108, 762, 1854, 1110, 2088, 2369, 2119, 1816, 805, 2362, 2099, 2086, 97, 2109, 788, 2098, 2116, 786, 2070, 2082, 767, 2107, 2120, 2059, 2372, 768, 1120, 763, 2097, 2072, 2053, 2080, 135, 765, 2050, 2066, 1846, 1821, 2048, 1331, 789, 134, 113, 1661, 1839, 1852, 1195, 2078, 75, 1662, 2102, 2213, 794, 2101, 2128, 117, 2124, 1317, 2060, 766, 2047, 1127, 807, 1326, 2096, 1325, 2367, 2049, 2103, 1823, 1116, 806, 91, 1329, 2212, 1321, 2077, 2075, 1817, 70, 790, 1185, 2105, 63, 64, 799, 962, 252, 2054, 1322, 102, 795, 1856, 1318, 158, 1126, 1125, 1857, 761, 1347, 82, 98, 1113, 2095, 1843, 968, 1121, 1847, 1187, 107, 2061, 782, 142, 148, 1133, 1132, 74, 793, 1850, 114, 1128, 964, 785, 86, 2, 160, 242, 1660, 100, 306, 302, 1188, 1343, 172, 236, 66, 222, 111, 2040, 258, 300, 104, 101, 244, 278, 304, 976, 298, 1330, 84, 71, 176, 182, 1186, 166, 186, 290, 250, 268, 296, 308, 69, 1102, 190, 764, 99, 741, 314, 154, 1820, 85, 194, 288, 2386, 94, 2065, 254, 146, 164, 284, 106, 178, 970, 978, 72, 174, 152, 310, 46, 180, 787, 292, 264, 248, 318, 998, 753, 168, 246, 2377, 2366, 274, 234, 286, 982, 196, 282, 984, 280, 988, 262, 228, 1840, 2373, 2365, 745, 67, 1040, 95, 986, 2068, 740, 1034, 188, 2043, 754, 918, 256, 294, 208, 202, 1342, 218, 1074, 266, 1072, 1082, 132, 204, 916, 1094, 1002, 2055, 276, 232, 1659, 206, 744, 920, 747, 802, 105, 972, 746, 210, 1004, 216, 1052, 26, 1822, 755, 1088, 65, 936, 214, 272, 260, 1056, 1026, 2123, 112, 924, 1124, 1054, 226, 934, 928, 96, 224, 270, 230, 93, 990, 54, 184, 952, 162, 312, 750, 1010, 198, 76, 751, 974, 2390, 1042, 1064, 756, 1014, 131, 150, 1084, 1062, 240, 1104, 58, 80, 2364, 192, 1086, 1066, 44, 1046, 1036, 926, 1058, 156, 1012, 1018, 238, 38, 1098, 980, 220, 1100, 78, 2062, 200, 1008, 743, 742, 83, 1119, 942, 1044, 60, 954, 1016, 2211, 34, 81, 2387, 1068, 944, 994, 212, 958, 1136, 24, 2368, 2115, 960, 946, 1032, 40, 1106, 922, 930, 1000, 1006, 73, 739, 32, 1076, 1038, 2391, 1092, 1346, 1080, 92, 50, 996, 1060, 48, 781, 1090, 940, 992, 948, 77, 79, 30, 1078, 108, 120, 1048, 28, 1096, 1030, 143, 1855, 1050, 1028, 950, 141, 1070, 52, 62, 1131, 133, 125, 122, 136, 126, 42, 138, 144, 115, 2046, 56, 123, 36, 2376, 938, 2106, 116, 966, 758, 757, 137, 140, 119], "count": [9669, 10497, 4485, 9670, 10498, 10496, 9317, 4484, 9668, 3409, 10499, 9671, 4486, 1084, 2035, 1851, 1848, 9318, 4487, 2055, 2001, 1108, 3067, 1540, 4483, 1092, 1979, 4482, 1082, 3066], "hitc_1_count": [3249.0, 2990.0, 2696.0, 2559.0, 2408.0, 2331.0, 2310.0, 2289.0, 2232.0, 2231.0, 2218.0, 2187.0, 2169.0, 2125.0, 2092.0, 2084.0, 2055.0, 1922.0, 1899.0, 1854.0, 1769.0, 1732.0, 1663.0, 1643.0, 1609.0, 1598.0, 1592.0, 1589.0, 1588.0, 1573.0, 1530.0, 1526.0, 1504.0, 1493.0, 1491.0, 1486.0, 1481.0, 1443.0, 1415.0, 1395.0, 1393.0, 1387.0, 1365.0, 1364.0, 1354.0, 1331.0, 1324.0, 1297.0, 1288.0, 1278.0, 1273.0, 1269.0, 1259.0, 1248.0, 1238.0, 1236.0, 1160.0, 1158.0, 1150.0, 1149.0, 1145.0, 1142.0, 1122.0, 1120.0, 1119.0, 1117.0, 1113.0, 1103.0, 1094.0, 1090.0, 1086.0, 1082.0, 1068.0, 1066.0, 1053.0, 1045.0, 1043.0, 1027.0, 1010.0, 1005.0, 1000.0, 997.0, 991.0, 985.0, 976.0, 973.0, 970.0, 947.0, 945.0, 938.0, 928.0, 905.0, 892.0, 864.0, 852.0, 850.0, 827.0, 815.0, 814.0, 813.0, 803.0, 801.0, 790.0, 785.0, 783.0, 779.0, 776.0, 773.0, 766.0, 764.0, 742.0, 741.0, 738.0, 726.0, 722.0, 721.0, 719.0, 712.0, 709.0, 701.0, 683.0, 679.0, 659.0, 648.0, 647.0, 646.0, 644.0, 642.0, 637.0, 636.0, 631.0, 630.0, 627.0, 626.0, 620.0, 617.0, 615.0, 607.0, 605.0, 604.0, 595.0, 593.0, 590.0, 587.0, 585.0, 579.0, 578.0, 575.0, 573.0, 569.0, 568.0, 567.0, 566.0, 564.0, 554.0, 553.0, 551.0, 550.0, 547.0, 546.0, 543.0, 541.0, 540.0, 539.0, 538.0, 537.0, 536.0, 534.0, 533.0, 531.0, 530.0, 527.0, 526.0, 525.0, 523.0, 521.0, 519.0, 518.0, 516.0, 513.0, 511.0, 509.0, 503.0, 499.0, 497.0, 492.0, 489.0, 485.0, 484.0, 483.0, 472.0, 470.0, 466.0, 464.0, 463.0, 462.0, 461.0, 456.0, 451.0, 444.0, 443.0, 437.0, 436.0, 431.0, 429.0, 427.0, 423.0, 422.0, 421.0, 419.0, 418.0, 416.0, 415.0, 414.0, 413.0, 412.0, 407.0, 405.0, 402.0, 400.0, 395.0, 392.0, 390.0, 385.0, 382.0, 378.0, 376.0, 375.0, 373.0, 370.0, 367.0, 366.0, 364.0, 361.0, 359.0, 352.0, 351.0, 350.0, 349.0, 348.0, 347.0, 345.0, 339.0, 336.0, 335.0, 333.0, 332.0, 331.0, 330.0, 329.0, 327.0, 325.0, 322.0, 321.0, 317.0, 316.0, 315.0, 314.0, 310.0, 308.0, 306.0, 305.0, 303.0, 302.0, 301.0, 300.0, 298.0, 297.0, 292.0, 291.0, 290.0, 288.0, 286.0, 283.0, 282.0, 279.0, 278.0, 277.0, 275.0, 274.0, 269.0, 267.0, 266.0, 265.0, 262.0, 260.0, 259.0, 256.0, 254.0, 253.0, 247.0, 246.0, 245.0, 241.0, 240.0, 239.0, 237.0, 231.0, 230.0, 228.0, 227.0, 226.0, 225.0, 224.0, 223.0, 219.0, 216.0, 214.0, 210.0, 207.0, 204.0, 203.0, 202.0, 198.0, 197.0, 195.0, 194.0, 193.0, 191.0, 190.0, 189.0, 186.0, 185.0, 182.0, 178.0, 177.0, 173.0, 171.0, 170.0, 169.0, 168.0, 166.0, 163.0, 161.0, 160.0, 158.0, 150.0, 140.0, 136.0, 122.0, 116.0, 111.0, 105.0, 99.0, 94.0, 93.0, 91.0, 87.0, 79.0, 72.0, 66.0, 65.0, 63.0, 56.0, 54.0, 47.0, 42.0, 36.0, 35.0, 33.0], "hitc_0_count": [6420.0, 7507.0, 6973.0, 1926.0, 7262.0, 7339.0, 7360.0, 7381.0, 7437.0, 8267.0, 8278.0, 7130.0, 7501.0, 7544.0, 7577.0, 7585.0, 8442.0, 7747.0, 7771.0, 7816.0, 2715.0, 7937.0, 8835.0, 8027.0, 8026.0, 8889.0, 8072.0, 8078.0, 8909.0, 8082.0, 8096.0, 8140.0, 8142.0, 8994.0, 7824.0, 9007.0, 8184.0, 8189.0, 8226.0, 8255.0, 3089.0, 9105.0, 8282.0, 8304.0, 8305.0, 8315.0, 8338.0, 7993.0, 9201.0, 3196.0, 3206.0, 8396.0, 8400.0, 2150.0, 8069.0, 8432.0, 3249.0, 8510.0, 8512.0, 8520.0, 9349.0, 8525.0, 8527.0, 3362.0, 8550.0, 9380.0, 8554.0, 9385.0, 8566.0, 8223.0, 9408.0, 9411.0, 8588.0, 9429.0, 8603.0, 8616.0, 8625.0, 8627.0, 9472.0, 9488.0, 3476.0, 9492.0, 8670.0, 9502.0, 8679.0, 8685.0, 8693.0, 3511.0, 9528.0, 8370.0, 8725.0, 3548.0, 3556.0, 9591.0, 192.0, 1171.0, 8817.0, 9649.0, 3658.0, 9671.0, 1036.0, 9685.0, 1222.0, 8514.0, 8516.0, 1061.0, 9713.0, 8534.0, 3705.0, 3708.0, 8544.0, 8904.0, 8907.0, 342.0, 8575.0, 8928.0, 9761.0, 3758.0, 8948.0, 9775.0, 3766.0, 1323.0, 8608.0, 3801.0, 9819.0, 1189.0, 3836.0, 437.0, 9852.0, 3840.0, 2767.0, 1398.0, 8682.0, 3848.0, 1404.0, 1405.0, 8687.0, 1408.0, 1409.0, 3864.0, 1418.0, 3869.0, 9062.0, 1430.0, 1431.0, 3889.0, 3891.0, 1445.0, 1448.0, 1450.0, 505.0, 1457.0, 9922.0, 3912.0, 3918.0, 1467.0, 1468.0, 8751.0, 1471.0, 1481.0, 1482.0, 1484.0, 1485.0, 1488.0, 3938.0, 538.0, 1492.0, 9957.0, 3944.0, 1516.0, 1497.0, 1498.0, 9133.0, 3951.0, 1502.0, 1504.0, 3957.0, 9143.0, 1510.0, 1512.0, 1514.0, 3966.0, 1519.0, 571.0, 573.0, 3973.0, 1526.0, 1532.0, 1536.0, 611.0, 1543.0, 10009.0, 1550.0, 1551.0, 1552.0, 612.0, 1585.0, 1565.0, 9203.0, 9205.0, 1572.0, 1573.0, 1574.0, 628.0, 1579.0, 1584.0, 640.0, 1592.0, 647.0, 1599.0, 9239.0, 9243.0, 1632.0, 4062.0, 662.0, 663.0, 9249.0, 1636.0, 666.0, 1617.0, 9252.0, 1640.0, 670.0, 1622.0, 1623.0, 1628.0, 8912.0, 1633.0, 684.0, 1635.0, 689.0, 692.0, 4095.0, 1650.0, 702.0, 9292.0, 1659.0, 1660.0, 8944.0, 1665.0, 1685.0, 717.0, 1689.0, 10134.0, 4123.0, 723.0, 1696.0, 1683.0, 733.0, 735.0, 760.0, 9323.0, 2722.0, 745.0, 4148.0, 748.0, 1700.0, 1207.0, 1702.0, 751.0, 9338.0, 4153.0, 754.0, 8987.0, 755.0, 1706.0, 757.0, 759.0, 4162.0, 1714.0, 1718.0, 4167.0, 768.0, 776.0, 1720.0, 770.0, 1725.0, 1727.0, 1749.0, 778.0, 1730.0, 4181.0, 1753.0, 783.0, 784.0, 786.0, 2770.0, 792.0, 4191.0, 1744.0, 793.0, 794.0, 1747.0, 798.0, 825.0, 4201.0, 9388.0, 1756.0, 806.0, 807.0, 833.0, 810.0, 815.0, 817.0, 1769.0, 818.0, 819.0, 1770.0, 843.0, 822.0, 824.0, 1775.0, 4225.0, 9413.0, 1286.0, 831.0, 1802.0, 4237.0, 9070.0, 838.0, 863.0, 868.0, 4246.0, 1762.0, 847.0, 853.0, 1805.0, 856.0, 857.0, 882.0, 9444.0, 860.0, 861.0, 865.0, 892.0, 870.0, 874.0, 877.0, 880.0, 4281.0, 1777.0, 910.0, 887.0, 889.0, 1807.0, 891.0, 9124.0, 893.0, 4293.0, 902.0, 894.0, 903.0, 10307.0, 895.0, 898.0, 899.0, 4306.0, 931.0, 911.0, 4313.0, 4314.0, 915.0, 939.0, 916.0, 918.0, 4318.0, 923.0, 924.0, 926.0, 4335.0, 944.0, 952.0, 972.0, 9195.0, 4366.0, 4374.0, 4379.0, 4385.0, 4391.0, 1015.0, 4393.0, 4397.0, 4399.0, 9590.0, 4411.0, 1042.0, 9604.0, 1021.0, 9614.0, 4427.0, 1028.0, 3019.0, 3024.0, 4448.0, 4450.0], "ratio": [0.336, 0.2848, 0.2788, 0.5706, 0.249, 0.2411, 0.2389, 0.2367, 0.2308, 0.2125, 0.2113, 0.2347, 0.2243, 0.2198, 0.2164, 0.2155, 0.1958, 0.1988, 0.1964, 0.1917, 0.3945, 0.1791, 0.1584, 0.1699, 0.1533, 0.1653, 0.1646, 0.1514, 0.1642, 0.1627, 0.1582, 0.1578, 0.1433, 0.1602, 0.142, 0.1537, 0.1532, 0.1492, 0.1463, 0.3111, 0.1327, 0.1434, 0.1412, 0.1411, 0.14, 0.1377, 0.1421, 0.1235, 0.2872, 0.285, 0.1317, 0.1312, 0.3693, 0.1339, 0.128, 0.2756, 0.12, 0.1198, 0.1189, 0.1094, 0.1184, 0.1181, 0.2502, 0.1158, 0.1066, 0.1155, 0.106, 0.1141, 0.1174, 0.1038, 0.1035, 0.1119, 0.1017, 0.1102, 0.1089, 0.1081, 0.1079, 0.0978, 0.0962, 0.2251, 0.0957, 0.1034, 0.095, 0.1025, 0.1019, 0.1009, 0.217, 0.0924, 0.1016, 0.0977, 0.2091, 0.207, 0.0862, 0.8229, 0.4246, 0.0881, 0.081, 0.1844, 0.0788, 0.4403, 0.0775, 0.3995, 0.086, 0.4268, 0.0748, 0.084, 0.1737, 0.1731, 0.083, 0.0792, 0.079, 0.6845, 0.0796, 0.0766, 0.0703, 0.1619, 0.0747, 0.0687, 0.1603, 0.3499, 0.0761, 0.0752, 0.1523, 0.0647, 0.3566, 0.1445, 0.0694, 0.5969, 0.0615, 0.1436, 0.1883, 0.313, 0.0683, 0.1418, 0.3101, 0.3096, 0.0676, 0.3081, 0.3076, 0.1383, 0.3032, 0.1372, 0.0628, 0.2973, 0.2968, 0.1322, 0.2899, 0.2885, 0.2875, 0.5341, 0.284, 0.0548, 0.1278, 0.1268, 0.2791, 0.2786, 0.0607, 0.2771, 0.2722, 0.2717, 0.2708, 0.2703, 0.2688, 0.1218, 0.5037, 0.2668, 0.0515, 0.1204, 0.2623, 0.2644, 0.2639, 0.0554, 0.1191, 0.2619, 0.2609, 0.2649, 0.1175, 0.0544, 0.258, 0.257, 0.256, 0.255, 0.2536, 0.4732, 0.4714, 0.114, 0.2501, 0.2472, 0.2452, 0.4486, 0.2418, 0.0466, 0.2383, 0.2378, 0.2373, 0.4354, 0.2287, 0.231, 0.0482, 0.048, 0.2275, 0.227, 0.2265, 0.4207, 0.2241, 0.2216, 0.4096, 0.2177, 0.4031, 0.2143, 0.0446, 0.0444, 0.0442, 0.2058, 0.0941, 0.3893, 0.3884, 0.0435, 0.2039, 0.3856, 0.2054, 0.043, 0.2019, 0.3819, 0.2029, 0.2025, 0.2, 0.1975, 0.369, 0.1966, 0.3644, 0.3616, 0.087, 0.1892, 0.3524, 0.0391, 0.1848, 0.1843, 0.04, 0.1818, 0.18, 0.3386, 0.1781, 0.0347, 0.0805, 0.333, 0.1747, 0.173, 0.3238, 0.172, 0.322, 0.3141, 0.0359, 0.1125, 0.3127, 0.0749, 0.31, 0.2162, 0.1636, 0.3072, 0.0343, 0.0738, 0.3044, 0.0354, 0.3035, 0.1617, 0.3017, 0.2998, 0.0718, 0.1577, 0.1558, 0.0705, 0.2915, 0.2894, 0.1548, 0.2897, 0.1489, 0.2823, 0.1499, 0.147, 0.2777, 0.1504, 0.2768, 0.2749, 0.0968, 0.2694, 0.0651, 0.143, 0.2685, 0.2675, 0.1415, 0.2638, 0.2554, 0.0631, 0.0292, 0.1371, 0.2565, 0.2555, 0.2482, 0.2528, 0.2463, 0.1307, 0.2454, 0.2445, 0.1302, 0.2392, 0.2417, 0.2399, 0.0578, 0.0265, 0.1649, 0.2334, 0.1231, 0.0551, 0.2269, 0.2211, 0.2223, 0.0249, 0.2166, 0.0535, 0.1194, 0.2186, 0.2131, 0.113, 0.2103, 0.2094, 0.204, 0.0233, 0.2066, 0.2057, 0.202, 0.1949, 0.1974, 0.1937, 0.191, 0.1882, 0.0453, 0.1021, 0.1787, 0.1817, 0.1799, 0.097, 0.178, 0.0207, 0.1762, 0.0426, 0.174, 0.1753, 0.018, 0.1744, 0.1716, 0.1707, 0.1679, 0.0397, 0.1597, 0.1596, 0.0381, 0.0379, 0.1559, 0.1525, 0.155, 0.1531, 0.037, 0.0882, 0.1485, 0.1476, 0.1458, 0.0334, 0.1292, 0.1282, 0.1227, 0.0131, 0.0259, 0.0247, 0.0234, 0.0221, 0.021, 0.0839, 0.0203, 0.0194, 0.0082, 0.065, 0.0161, 0.0596, 0.0067, 0.0581, 0.0058, 0.0125, 0.0499, 0.0153, 0.0137, 0.008, 0.0078, 0.0074], "acid": [2370, 541, 2009, 72, 1975, 1973, 1939, 1971, 1990, 499, 534, 697, 1970, 2376, 1997, 1120, 542, 2369, 1981, 1968, 66, 1991, 525, 1980, 2002, 523, 1952, 1964, 504, 1989, 1998, 1941, 2379, 505, 707, 500, 1979, 1954, 1935, 1962, 104, 502, 1932, 1948, 1144, 1125, 1930, 906, 526, 103, 82, 1015, 1137, 1804, 757, 1960, 44, 1016, 1984, 2075, 531, 1983, 2010, 86, 2006, 892, 1942, 503, 1929, 714, 544, 901, 1978, 900, 2374, 1931, 1985, 1127, 703, 543, 60, 904, 2074, 896, 1959, 1957, 1121, 39, 527, 747, 1987, 32, 33, 536, 622, 167, 1936, 897, 71, 532, 1830, 893, 120, 713, 712, 1831, 498, 914, 51, 67, 700, 1977, 1141, 625, 708, 1145, 749, 76, 1943, 519, 111, 115, 720, 719, 43, 530, 1802, 83, 715, 623, 522, 55, 1, 121, 162, 1014, 69, 194, 192, 750, 910, 127, 159, 35, 152, 80, 1922, 170, 191, 73, 70, 163, 180, 193, 629, 190, 905, 53, 40, 129, 132, 748, 124, 134, 186, 166, 175, 189, 195, 38, 692, 136, 501, 68, 478, 198, 118, 1124, 54, 138, 185, 2393, 63, 1947, 168, 114, 123, 183, 75, 130, 626, 630, 41, 128, 117, 196, 23, 131, 524, 187, 173, 165, 200, 640, 490, 125, 164, 2384, 2373, 178, 158, 184, 632, 139, 182, 633, 181, 635, 172, 155, 1138, 2380, 2372, 482, 36, 661, 64, 634, 1950, 477, 658, 135, 1925, 491, 600, 169, 188, 145, 142, 909, 150, 678, 174, 677, 682, 101, 143, 599, 688, 642, 1937, 179, 157, 1013, 144, 481, 601, 484, 539, 74, 627, 483, 146, 643, 149, 667, 13, 1126, 492, 685, 34, 609, 148, 177, 171, 669, 654, 2005, 81, 603, 711, 668, 154, 608, 605, 65, 153, 176, 156, 62, 636, 27, 133, 617, 122, 197, 487, 646, 140, 45, 488, 628, 2397, 662, 673, 493, 648, 100, 116, 683, 672, 161, 693, 29, 49, 2371, 137, 684, 674, 22, 664, 659, 604, 670, 119, 647, 650, 160, 19, 690, 631, 151, 691, 47, 1944, 141, 645, 480, 479, 52, 706, 612, 663, 30, 618, 649, 2073, 17, 50, 2394, 675, 613, 638, 147, 620, 722, 12, 2375, 2001, 621, 614, 657, 20, 694, 602, 606, 641, 644, 42, 476, 16, 679, 660, 2398, 687, 913, 681, 61, 25, 639, 671, 24, 518, 686, 611, 637, 615, 46, 48, 15, 680, 77, 89, 665, 14, 689, 656, 112, 1829, 666, 655, 616, 110, 676, 26, 31, 718, 102, 94, 91, 105, 95, 21, 107, 113, 84, 1928, 28, 92, 18, 2383, 610, 1988, 85, 624, 495, 494, 106, 109, 88], "assay_component_endpoint_name": ["TOX21_PXR_agonist", "TOX21_TR_LUC_GH3_Antagonist", "TOX21_PR_BLA_Antagonist_ratio", "ATG_PXRE_CIS", "TOX21_RT_HEK293_GLO_40hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability", "TOX21_ERR_Antagonist", "TOX21_RT_HEK293_GLO_24hr_viability", "TOX21_SHH_3T3_GLI3_Antagonist", "TOX21_AR_BLA_Antagonist_ratio", "TOX21_MMP_ratio", "TOX21_ARE_BLA_Agonist_ratio", "TOX21_RT_HEK293_GLO_16hr_viability", "TOX21_CASP3_CHO_viability", "TOX21_ERb_BLA_Antagonist_ratio", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_TR_LUC_GH3_Antagonist_viability", "TOX21_PXR_viability", "TOX21_RT_HEPG2_FLO_40hr_viability", "TOX21_RT_HEK293_GLO_08hr_viability", "ATG_NRF2_ARE_CIS", "TOX21_SHH_3T3_GLI3_Antagonist_viability", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_RT_HEPG2_FLO_32hr_viability", "TOX21_ERb_BLA_Agonist_viability", "TOX21_ERa_BLA_Antagonist_ratio", "TOX21_PGC_ERR_Antagonist", "TOX21_RT_HEK293_FLO_40hr_viability", "TOX21_Aromatase_Inhibition", "TOX21_SHH_3T3_GLI3_Agonist_viability", "TOX21_ERb_BLA_Antagonist_viability", "TOX21_ERR_viability", "TOX21_SBE_BLA_Antagonist_ratio", "TOX21_Aromatase_Inhibition_viability", "TOX21_FXR_BLA_Antagonist_ratio", "TOX21_AR_BLA_Antagonist_viability", "TOX21_RT_HEPG2_FLO_24hr_viability", "TOX21_PGC_ERR_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "TOX21_RT_HEK293_FLO_32hr_viability", "ATG_PXR_TRANS", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_CAR_Antagonist_viability", "TOX21_HRE_BLA_Agonist_viability", "TOX21_AP1_BLA_Agonist_ratio", "TOX21_RXR_BLA_Agonist_viability", "TOX21_CAR_Agonist_viability", "TOX21_VDR_BLA_Agonist_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "ATG_PPARg_TRANS", "ATG_VDRE_CIS", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RAR_LUC_Antagonist", "ACEA_ER_AUC_viability", "TOX21_PPARd_BLA_Agonist_viability", "TOX21_RT_HEK293_FLO_24hr_viability", "ATG_ERE_CIS", "TOX21_RORg_LUC_CHO_Antagonist_viability", "TOX21_RT_HEPG2_GLO_16hr_viability", "TOX21_RT_HEPG2_GLO_24hr_viability", "TOX21_GR_BLA_Antagonist_ratio", "TOX21_RT_HEPG2_GLO_08hr_viability", "TOX21_PR_BLA_Antagonist_viability", "ATG_ERa_TRANS", "TOX21_PR_BLA_Agonist_viability", "TOX21_p53_BLA_p2_ratio", "TOX21_H2AX_HTRF_CHO_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", "TOX21_CAR_Agonist", "TOX21_PPARg_BLA_Antagonist_ratio", "TOX21_AhR_LUC_Agonist_viability", "TOX21_p53_BLA_p4_viability", "TOX21_RT_HEPG2_FLO_16hr_viability", "TOX21_p53_BLA_p4_ratio", "TOX21_CASP3_HEPG2_viability", "TOX21_CAR_Antagonist", "TOX21_RT_HEPG2_GLO_32hr_viability", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", "TOX21_p53_BLA_p1_ratio", "TOX21_AhR_LUC_Agonist", "ATG_MRE_CIS", "TOX21_p53_BLA_p5_ratio", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", "TOX21_p53_BLA_p3_ratio", "TOX21_RT_HEK293_FLO_16hr_viability", "TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", "ATG_DR4_LXR_CIS", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", "TOX21_ARE_BLA_agonist_viability", "TOX21_RT_HEPG2_GLO_40hr_viability", "ATG_Ahr_CIS", "ATG_AP_1_CIS", "TOX21_MMP_viability", "LTEA_HepaRG_CYP1A1", "BSK_hDFCGF_Proliferation", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", "TOX21_p53_BLA_p3_viability", "ATG_PPRE_CIS", "TOX21_GR_BLA_Antagonist_viability", "ACEA_AR_antagonist_80hr", "TOX21_p53_BLA_p2_viability", "BSK_3C_Proliferation", "TOX21_PPARd_BLA_Antagonist_viability", "TOX21_PPARd_BLA_Antagonist_ratio", "ACEA_AR_antagonist_AUC_viability", "TOX21_AR_BLA_Agonist_ratio", "TOX21_NFkB_BLA_agonist_viability", "ATG_HIF1a_CIS", "ATG_Oct_MLP_CIS", "TOX21_HSE_BLA_Agonist_ratio", "TOX21_RT_HEPG2_FLO_08hr_viability", "TOX21_H2AX_HTRF_CHO_Agonist_ratio", "LTEA_HepaRG_CYP2B6", "TOX21_FXR_BLA_Antagonist_viability", "TOX21_AP1_BLA_Agonist_viability", "TOX21_p53_BLA_p1_viability", "ATG_SREBP_CIS", "TOX21_HDAC_Inhibition", "TOX21_ELG1_LUC_Agonist_viability", "ATG_RXRb_TRANS", "BSK_3C_HLADR", "TOX21_VDR_BLA_Antagonist_viability", "TOX21_VDR_BLA_Antagonist_ratio", "ATG_EGR_CIS", "TOX21_GR_BLA_Agonist_ratio", "ACEA_AR_agonist_AUC_viability", "ATG_Xbp1_CIS", "TOX21_PPARg_BLA_Antagonist_viability", "LTEA_HepaRG_CYP1A2", "TOX21_ERa_BLA_Agonist_ratio", "ATG_ISRE_CIS", "ACEA_ER_80hr", "BSK_3C_SRB", "BSK_hDFCGF_IP10", "TOX21_RAR_LUC_Agonist_viability", "ATG_Pax6_CIS", "BSK_SAg_Eselectin", "BSK_SAg_CD40", "TOX21_FXR_BLA_agonist_viability", "TOX21_ESRE_BLA_viability", "BSK_4H_Eotaxin3", "BSK_hDFCGF_CollagenIII", "ATG_BRE_CIS", "BSK_CASM3C_Proliferation", "ATG_TCF_b_cat_CIS", "TOX21_TSHR_HTRF_Agonist_ratio", "BSK_hDFCGF_VCAM1", "BSK_SAg_CD38", "ATG_RORE_CIS", "ATG_PBREM_CIS", "BSK_hDFCGF_MCSF", "BSK_LPS_CD40", "BSK_SAg_CD69", "LTEA_HepaRG_CYP2E1", "BSK_LPS_VCAM1", "TOX21_p53_BLA_p5_viability", "ATG_HSE_CIS", "ATG_DR5_RAR_CIS", "BSK_4H_Pselectin", "BSK_4H_VCAM1", "TOX21_HSE_BLA_agonist_viability", "BSK_3C_uPAR", "BSK_BE3C_HLADR", "BSK_LPS_PGE2", "BSK_hDFCGF_PAI1", "BSK_KF3CT_MMP9", "BSK_LPS_TNFa", "BSK_SAg_IL8", "ATG_CRE_CIS", "LTEA_HepaRG_UGT1A1", "BSK_BE3C_IP10", "TOX21_AR_LUC_MDAKB2_Agonist", "ATG_p53_CIS", "OT_AR_ARSRC1_0960", "BSK_SAg_PBMCCytotoxicity", "BSK_3C_MCP1", "TOX21_RXR_BLA_Agonist_ratio", "ATG_IR1_CIS", "BSK_BE3C_MMP1", "BSK_LPS_MCSF", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", "ATG_NF_kB_CIS", "TOX21_HRE_BLA_Agonist_ratio", "BSK_hDFCGF_SRB", "BSK_3C_Eselectin", "BSK_3C_TissueFactor", "BSK_LPS_IL8", "ATG_Sp1_CIS", "BSK_4H_SRB", "LTEA_HepaRG_CYP2C19", "LTEA_HepaRG_CYP3A4", "ATG_E_Box_CIS", "BSK_4H_MCP1", "BSK_3C_IL8", "BSK_SAg_MCP1", "APR_HepG2_CellLoss_72hr", "BSK_4H_uPAR", "TOX21_ERa_BLA_Antagonist_viability", "BSK_LPS_SRB", "BSK_KF3CT_IP10", "BSK_hDFCGF_MMP1", "BSK_SAg_SRB", "LTEA_HepaRG_FABP1", "OT_FXR_FXRSRC1_0480", "BSK_3C_VCAM1", "BSK_hDFCGF_MIG", "TOX21_SBE_BLA_Agonist_viability", "TOX21_CASP3_HEPG2", "BSK_KF3CT_TIMP2", "BSK_CASM3C_VCAM1", "BSK_LPS_MCP1", "LTEA_HepaRG_CYP3A7", "BSK_BE3C_PAI1", "BSK_LPS_IL1a", "LTEA_HepaRG_CYP4A11", "BSK_LPS_Eselectin", "LTEA_HepaRG_CYP7A1", "BSK_KF3CT_IL1a", "BSK_CASM3C_Thrombomodulin", "TOX21_RAR_LUC_Antagonist_viability", "TOX21_SBE_BLA_Antagonist_viability", "TOX21_TRHR_HEK293_antagonist", "OT_ER_ERaERb_1440", "ATG_C_EBP_CIS", "LTEA_HepaRG_IGF1", "ATG_NFI_CIS", "LTEA_HepaRG_CYP4A22", "TOX21_PGC_ERR_Agonist", "OT_AR_ARSRC1_0480", "LTEA_HepaRG_HMGCS2", "BSK_BE3C_IL1a", "TOX21_TSHR_HTRF_Antagonist_ratio", "OT_FXR_FXRSRC1_1440", "LTEA_HepaRG_ABCB11", "BSK_hDFCGF_TIMP1", "BSK_LPS_TissueFactor", "BSK_CASM3C_HLADR", "BSK_BE3C_tPA", "TOX21_ESRE_BLA_ratio", "BSK_CASM3C_MCSF", "LTEA_HepaRG_PEG10", "BSK_KF3CT_MCP1", "LTEA_HepaRG_PDK4", "LTEA_HepaRG_SLC22A1", "ATG_PPARa_TRANS", "BSK_BE3C_uPA", "LTEA_HepaRG_ABCB1", "LTEA_HepaRG_THRSP", "LTEA_HepaRG_FASN", "TOX21_ERR_Agonist", "BSK_KF3CT_uPA", "BSK_CASM3C_uPAR", "TOX21_RAR_LUC_Agonist", "BSK_BE3C_uPAR", "OT_ER_ERaERb_0480", "LTEA_HepaRG_ABCC2", "OT_ER_ERbERb_1440", "TOX21_PPARg_BLA_Agonist_ratio", "ATG_Sox_CIS", "LTEA_HepaRG_CYP2C8", "OT_ER_ERbERb_0480", "BSK_CASM3C_IL6", "LTEA_HepaRG_FMO3", "BSK_CASM3C_MCP1", "LTEA_HepaRG_KRT19", "APR_HepG2_CellLoss_24hr", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", "OT_NURR1_NURR1RXRa_0480", "LTEA_HepaRG_SULT2A1", "ATG_AP_2_CIS", "LTEA_HepaRG_APOA5", "BSK_CASM3C_LDLR", "BSK_KF3CT_TGFb1", "BSK_KF3CT_ICAM1", "LTEA_HepaRG_LPL", "LTEA_HepaRG_GSTA2", "TOX21_PR_BLA_Agonist_ratio", "ATG_TGFb_CIS", "LTEA_HepaRG_ABCG2", "TOX21_PPARd_BLA_Agonist_ratio", "LTEA_HepaRG_LIPC", "BSK_CASM3C_SRB", "LTEA_HepaRG_ALPP", "LTEA_HepaRG_ACOX1", "ATG_NRF1_CIS", "BSK_CASM3C_SAA", "BSK_KF3CT_SRB", "BSK_CASM3C_TissueFactor", "ATG_Myc_CIS", "LTEA_HepaRG_DDIT3", "APR_HepG2_MitoticArrest_72hr", "BSK_4H_VEGFRII", "LTEA_HepaRG_CAT", "BSK_3C_Thrombomodulin", "BSK_SAg_MIG", "OT_ERa_GFPERaERE_0120", "LTEA_HepaRG_GADD45A", "BSK_BE3C_SRB", "ATG_Ets_CIS", "OT_ERa_GFPERaERE_0480", "LTEA_HepaRG_CYP2C9", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", "LTEA_HepaRG_IGFBP1", "LTEA_HepaRG_MYC", "OT_NURR1_NURR1RXRa_1440", "LTEA_HepaRG_GADD45G", "ATG_NURR1_TRANS", "BSK_3C_ICAM1", "LTEA_HepaRG_SLCO1B1", "LTEA_HepaRG_MMP3", "BSK_hDFCGF_IL8", "LTEA_HepaRG_UGT1A6", "APR_HepG2_P-H2AX_72hr", "ATG_GLI_CIS", "TOX21_TRHR_HEK293_agonist", "BSK_BE3C_MIG", "LTEA_HepaRG_STAT3", "LTEA_HepaRG_NFE2L2", "APR_HepG2_CellCycleArrest_72hr", "LTEA_HepaRG_IL6R", "LTEA_HepaRG_HSPA1A", "LTEA_HepaRG_ACLY", "LTEA_HepaRG_MIR122", "BSK_3C_MIG", "LTEA_HepaRG_GADD45B", "LTEA_HepaRG_GCLM", "BSK_hDFCGF_EGFR", "APR_HepG2_P-H2AX_24hr", "LTEA_HepaRG_TNFRSF1A", "LTEA_HepaRG_CYP3A5", "BSK_CASM3C_MIG", "LTEA_HepaRG_TP53", "ATG_FoxO_CIS", "TOX21_HDAC_Inhibition_viability", "BSK_BE3C_TGFb1", "LTEA_HepaRG_FOXO3", "OT_ER_ERaERa_1440", "OT_ER_ERaERa_0480", "ATG_HNF6_CIS", "TOX21_FXR_BLA_Agonist_ratio", "LTEA_HepaRG_BCL2", "LTEA_HepaRG_IL6", "APR_HepG2_p53Act_72hr", "LTEA_HepaRG_CCND1", "LTEA_HepaRG_GCLC", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "APR_HepG2_MitoticArrest_24hr", "ATG_GRE_CIS", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", "LTEA_HepaRG_NFKB1", "LTEA_HepaRG_BCL2L11", "LTEA_HepaRG_EGR1", "BSK_CASM3C_IL8", "LTEA_HepaRG_CDKN1A", "LTEA_HepaRG_LDH_cytotoxicity", "APR_HepG2_CellCycleArrest_24hr", "TOX21_CASP3_CHO", "TOX21_ERb_BLA_Agonist_ratio", "LTEA_HepaRG_CFLAR", "LTEA_HepaRG_BID", "LTEA_HepaRG_HIF1A", "APR_HepG2_p53Act_24hr", "LTEA_HepaRG_XBP1", "LTEA_HepaRG_ABCC3", "LTEA_HepaRG_ADK", "LTEA_HepaRG_FAS", "LTEA_HepaRG_FOXO1", "ATG_E2F_CIS", "OT_AR_ARELUC_AG_1440", "APR_HepG2_MitoMembPot_24hr", "LTEA_HepaRG_PPP2R4", "LTEA_HepaRG_ICAM1", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", "LTEA_HepaRG_TGFB1", "TOX21_NFkB_BLA_agonist_ratio", "LTEA_HepaRG_SDHB", "ATG_Myb_CIS", "APR_HepG2_MitoMass_72hr", "LTEA_HepaRG_EZR", "LTEA_HepaRG_MMP10", "APR_HepG2_MicrotubuleCSK_72hr", "TOX21_ELG1_LUC_Agonist", "LTEA_HepaRG_TGFA", "LTEA_HepaRG_BAX", "LTEA_HepaRG_EGF", "LTEA_HepaRG_CASP3", "ATG_FoxA2_CIS", "ATG_GATA_CIS", "APR_HepG2_MitoMass_24hr", "LTEA_HepaRG_PTEN", "ATG_STAT3_CIS", "ATG_FXR_TRANS", "LTEA_HepaRG_JUN", "APR_HepG2_MicrotubuleCSK_24hr", "LTEA_HepaRG_TIMP1", "LTEA_HepaRG_HGF", "ATG_THRa1_TRANS", "ACEA_AR_agonist_80hr", "LTEA_HepaRG_KCNK1", "LTEA_HepaRG_GSTM3", "LTEA_HepaRG_CASP8", "ATG_RXRa_TRANS", "LTEA_HepaRG_NQO1", "APR_HepG2_MitoMembPot_72hr", "APR_HepG2_StressKinase_72hr", "TOX21_VDR_BLA_Agonist_ratio", "ATG_PPARd_TRANS", "ATG_LXRa_TRANS", "ATG_GR_TRANS", "ATG_RARa_TRANS", "ATG_LXRb_TRANS", "APR_HepG2_StressKinase_24hr", "ATG_RARg_TRANS", "ATG_VDR_TRANS", "ATG_AR_TRANS", "TOX21_TSHR_wt_Agonist_HTRF_ratio", "APR_HepG2_NuclearSize_72hr", "ATG_HNF4a_TRANS", "APR_HepG2_NuclearSize_24hr", "TOX21_SBE_BLA_Agonist_ratio", "LTEA_HepaRG_BAD", "TOX21_SHH_3T3_GLI3_Agonist", "ATG_CAR_TRANS", "LTEA_HepaRG_CYP24A1", "OT_PPARg_PPARgSRC1_1440", "OT_PPARg_PPARgSRC1_0480", "ATG_RARb_TRANS", "ATG_RORg_TRANS", "ATG_ERRg_TRANS"], "export_ready": [1], "internal_ready": [1], "assay_component_endpoint_desc": ["Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.", "Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PXRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "Data from the assay component TOX21_SHH_3T3_GLI3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", "Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_MMP_ratio was analyzed into 1 assay endpoint. The assay endpoin, TOX21_MMP_ratio, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.", "TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "The assay component endpoint  TOX21_PXR_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NRF2_ARE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.", "TOX21_SHH_3T3_GLI3_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.", "TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_VDRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.", "Data from the assay component ACEA_ER_AUC_viability was analyzed  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_ERE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_ERa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "Data from the assay component TOX21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_AhR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "The assay component endpoint  TOX21_CASP3_HEPG2_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_CAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Antagonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "TOX21_RT_HEPG2_GLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.", "Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_MRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", "Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter,  gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.", "TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_DR4_LXR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_DR4_LXR_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2 and NR1H3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_RT_HEPG2_GLO_40hr_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Ahr_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain or loss-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", "Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_AP_1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component LTEA_HepaRG_CYP1A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP1A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_hDFCGF_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PPRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component BSK_3C_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_3C_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", "TOX21_PPARd_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_AR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HIF1a_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", "Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Oct_MLP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.", "Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.", "TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability", "Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.", "Data from the assay component LTEA_HepaRG_CYP2B6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2B6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "TOX21_FXR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.", "TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_SREBP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", "Data from the assay component TOX21_HDAC_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HDAC_Inhibition, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HDAC1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", "TOX21_ELG1_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component BSK_3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", "TOX21_VDR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component TOX21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_EGR_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", "Data from the assay component TOX21_GR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ACEA_AR_AUC_viability was analyzed  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. \r\nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Xbp1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component LTEA_HepaRG_CYP1A2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP1A2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component TOX21_ERa_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ATG_ISRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_ISRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene IRF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is interferon regulatory factors.", "Data from the assay component ACEA_ER_80hr was analyzed into 1 assay endpoint. \r\nThis assay endpoint, ACEA_ER_80hr_Positive, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component BSK_3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component BSK_hDFCGF_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Pax6_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.", "Data from the assay component BSK_SAg_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", "Data from the assay component BSK_SAg_CD40 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD40, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", "TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component BSK_4H_Eotaxin3 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_Eotaxin3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_CollagenIII, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is collagen.", "Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_BRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.", "Data from the assay component BSK_CASM3C_Proliferation was analyzed into 1 assay endpoint. \nThis assay endpoint, BSK_CASM3C_Proliferation, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of total protein for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", "Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TCF_b_cat_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.", "Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", "Data from the assay component BSK_SAg_CD38 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD38, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is other cytokine.", "Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_RORE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_PBREM_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component BSK_hDFCGF_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", "Data from the assay component BSK_LPS_CD40 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_CD40, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", "Data from the assay component BSK_SAg_CD69 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_CD69, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", "Data from the assay component LTEA_HepaRG_CYP2E1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2E1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component BSK_LPS_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", "TOX21_p53_BLA_p5_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HSE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.", "Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_DR5_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component BSK_4H_Pselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_Pselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", "Data from the assay component BSK_4H_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", "TOX21_HSE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component BSK_3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", "Data from the assay component BSK_BE3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", "Data from the assay component BSK_LPS_PGE2 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_PGE2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", "Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_PAI1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator inhibitor.", "Data from the assay component BSK_KF3CT_MMP9 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_MMP9, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", "Data from the assay component BSK_LPS_TNFa was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_TNFa, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is inflammatory factor.", "Data from the assay component BSK_SAg_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_CRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "Data from the assay component LTEA_HepaRG_UGT1A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_UGT1A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is glucuronosyltransferase.", "Data from the assay component BSK_BE3C_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ATG_p53_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_p53_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TP53. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", "Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_PBMCCytotoxicity, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the viability. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component BSK_3C_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component TOX21_RXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RXR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RXRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where subfamily is NF-kappa B.", "Data from the assay component ATG_IR1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_IR1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component BSK_BE3C_MMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_MMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", "Data from the assay component BSK_LPS_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive analysis fitting direction relative to DHT as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", "Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NF_kB_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.", "Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.", "Data from the assay component BSK_hDFCGF_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component BSK_3C_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", "Data from the assay component BSK_3C_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", "Data from the assay component BSK_LPS_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Sp1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", "Data from the assay component BSK_4H_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component LTEA_HepaRG_CYP2C19 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C19, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component LTEA_HepaRG_CYP3A4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component ATG_E_Box_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_E_Box_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene USF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", "Data from the assay component BSK_4H_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component BSK_3C_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component BSK_SAg_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellLoss_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", "Data from the assay component BSK_4HAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_4HAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", "TOX21_ERa_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component BSK_LPS_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component BSK_KF3CT_IP10 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_IP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", "Data from the assay component BSK_SAg_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component LTEA_HepaRG_FABP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FABP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is fatty acid carrier protein.", "Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component BSK_3C_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", "Data from the assay component BSK_hDFCGF_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "The assay component endpoint  TOX21_SBE_BLA_Agonist_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "The assay component endpoint  TOX21_CASP3_HEPG2 was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_HEPG2 assay is a homogeneous, luminescent assay that measures caspase-3 activity following compound treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.", "Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_TIMP2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", "Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_VCAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", "Data from the assay component BSK_LPS_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component LTEA_HepaRG_CYP3A7 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A7, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component BSK_BE3C_PAI1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_PAI1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator inhibitor.", "Data from the assay component BSK_LPS_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component LTEA_HepaRG_CYP4A11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP4A11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component BSK_LPS_Eselectin was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_Eselectin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is selectins.", "Data from the assay component LTEA_HepaRG_CYP7A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP7A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component BSK_KF3CT_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_Thrombomodulin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", "TOX21_RAR_LUC_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "The assay component endpoint  TOX21_SBE_BLA_Antagonist_viability was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.", "TOX21_TRHR_HEK293_Antagonist  used a type of biochemical reporter where loss-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_C_EBP_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "Data from the assay component LTEA_HepaRG_IGF1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IGF1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is insulin-like.", "Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NFI_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.", "Data from the assay component LTEA_HepaRG_CYP4A22 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP4A22, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component TOX21_PGC_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component LTEA_HepaRG_HMGCS2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HMGCS2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is HMG-CoA synthase.", "Data from the assay component BSK_BE3C_IL1a was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_IL1a, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component TOX21_TSHR_HTRF_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this one serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component LTEA_HepaRG_ABCB11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCB11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", "Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_TIMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", "Data from the assay component BSK_LPS_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_LPS_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", "Data from the assay component BSK_CASM3C_HLADR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_HLADR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is MHC Class II.", "Data from the assay component BSK_BE3C_tPA was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_tPA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", "Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.", "Data from the assay component BSK_CASM3C_MCSF was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MCSF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is colony stimulating factor.", "Data from the assay component LTEA_HepaRG_PEG10 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PEG10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component BSK_KF3CT_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component LTEA_HepaRG_PDK4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PDK4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is serine/threonine kinase.", "Data from the assay component LTEA_HepaRG_SLC22A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLC22A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is organic cation transporter.", "Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component BSK_BE3CA was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3CA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", "Data from the assay component LTEA_HepaRG_ABCB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", "Data from the assay component LTEA_HepaRG_THRSP was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_THRSP, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is NR mediated metabolism.", "Data from the assay component LTEA_HepaRG_FASN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FASN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is fatty acid synthase.", "Data from the assay component TOX21_ERR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "Data from the assay component BSK_KF3CTA was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CTA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is serine protease.", "Data from the assay component BSK_CASM3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", "Data from the assay component TOX21_RAR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.", "Data from the assay component BSK_BE3CAR was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3CAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is plasmogen activator.", "Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component LTEA_HepaRG_ABCC2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCC2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", "Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_PPARg_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Sox_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is HMG box protein.", "Data from the assay component LTEA_HepaRG_CYP2C8 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component BSK_CASM3C_IL6 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_IL6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component LTEA_HepaRG_FMO3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FMO3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is dioxygenase.", "Data from the assay component BSK_CASM3C_MCP1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MCP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component LTEA_HepaRG_KRT19 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_KRT19, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the filaments intended target family, where the subfamily is keratin.", "Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellLoss_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the viability at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", "Data from the assay component TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component LTEA_HepaRG_SULT2A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SULT2A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is sulfotransferase.", "Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_AP_2_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-turn-helix leucine zipper.", "Data from the assay component LTEA_HepaRG_APOA5 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_APOA5, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the apolipoprotein intended target family, where the subfamily is Steatosis.", "Data from the assay component BSK_CASM3C_LDLR was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_LDLR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the misc protein intended target family, where the subfamily is LDL receptor.", "Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_TGFb1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", "Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", "Data from the assay component LTEA_HepaRG_LPL was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LPL, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is lipase.", "Data from the assay component LTEA_HepaRG_GSTA2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GSTA2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is alkyl and aryl transferase.", "Data from the assay component TOX21_PR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_TGFb_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", "Data from the assay component LTEA_HepaRG_ABCG2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCG2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", "Data from the assay component TOX21_PPARd_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component LTEA_HepaRG_LIPC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LIPC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the esterase intended target family, where the subfamily is lipase.", "Data from the assay component BSK_CASM3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component LTEA_HepaRG_ALPP was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ALPP, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_ACOX1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ACOX1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidase intended target family, where the subfamily is steatosis.", "Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_NRF1_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.", "Data from the assay component BSK_CASM3C_SAA was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_SAA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is apolipoproteins.", "Data from the assay component BSK_KF3CT_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_KF3CT_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_TissueFactor, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is coagulation factor.", "Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Myc_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", "Data from the assay component LTEA_HepaRG_DDIT3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_DDIT3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MitoticArrest_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", "Data from the assay component BSK_4H_VEGFRII was analyzed into 1 assay endpoint. This assay endpoint, BSK_4H_VEGFRII, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", "Data from the assay component LTEA_HepaRG_CAT was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CAT, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the catalase intended target family, where the subfamily is oxidative stress.", "Data from the assay component BSK_3C_Thrombomodulin was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_Thrombomodulin, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is rhodopsin-like receptor.", "Data from the assay component BSK_SAg_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_SAg_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component LTEA_HepaRG_GADD45A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Oxidative Stress.", "Data from the assay component BSK_BE3C_SRB was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_SRB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component ATG_Ets_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Ets_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ETS1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is winged helix-turn-helix.", "Data from the assay component OT_ERa_GFPERaERE_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ERa_EREGFP_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component LTEA_HepaRG_CYP2C9 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP2C9, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist, was analyzed in the positive analysis fitting direction relative to DHT as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", "Data from the assay component LTEA_HepaRG_IGFBP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IGFBP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is hormone carrier protein.", "Data from the assay component LTEA_HepaRG_MYC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MYC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.", "Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component LTEA_HepaRG_GADD45G was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45G, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mutagenicity response intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_NURR1_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "Data from the assay component BSK_3C_ICAM1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", "Data from the assay component LTEA_HepaRG_SLCO1B1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SLCO1B1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is organic anion transporter.", "Data from the assay component LTEA_HepaRG_MMP3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MMP3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", "Data from the assay component BSK_hDFCGF_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component LTEA_HepaRG_UGT1A6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_UGT1A6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is glucuronosyltransferase.", "Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_P-H2AX_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.", "Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GLI_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", "TOX21_TRHR_HEK293_Agonist  used a type of biochemical reporter where gain-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "Data from the assay component BSK_BE3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component LTEA_HepaRG_STAT3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_STAT3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.", "Data from the assay component LTEA_HepaRG_NFE2L2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NFE2L2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellCycleArrest_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", "Data from the assay component LTEA_HepaRG_IL6R was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IL6R, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is JAK-STAT cytokine receptor.", "Data from the assay component LTEA_HepaRG_HSPA1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HSPA1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.", "Data from the assay component LTEA_HepaRG_ACLY was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ACLY, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the lyase intended target family, where the subfamily is steatosis.", "Data from the assay component LTEA_HepaRG_MIR122 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MIR122, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the microrna intended target family, where the subfamily is post-transcriptional regulation.", "Data from the assay component BSK_3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component LTEA_HepaRG_GADD45B was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GADD45B, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mutagenicity response intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_GCLM was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GCLM, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ligase intended target family, where the subfamily is C-N ligase.", "Data from the assay component BSK_hDFCGF_EGFR was analyzed into 1 assay endpoint. This assay endpoint, BSK_hDFCGF_EGFR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is receptor tyrosine kinase.", "Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_P-H2AX_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.", "Data from the assay component LTEA_HepaRG_TNFRSF1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TNFRSF1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is TNF receptor.", "Data from the assay component LTEA_HepaRG_CYP3A5 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP3A5, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component BSK_CASM3C_MIG was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_MIG, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is chemotactic factor.", "Data from the assay component LTEA_HepaRG_TP53 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TP53, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", "Data from the assay component ATG_FoxO_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_FoxO_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXO1 and FOXO3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", "TOX21_HDAC_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.", "Data from the assay component BSK_BE3C_TGFb1 was analyzed into 1 assay endpoint. This assay endpoint, BSK_BE3C_TGFb1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", "Data from the assay component LTEA_HepaRG_FOXO3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FOXO3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", "Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ATG_HNF6_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_HNF6_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ONECUT1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is homeobox protein.", "Data from the assay component TOX21_FXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component LTEA_HepaRG_BCL2 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BCL2, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_IL6 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_IL6, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_p53Act_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", "Data from the assay component LTEA_HepaRG_CCND1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CCND1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_GCLC was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GCLC, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ligase intended target family, where the subfamily is C-N ligase.", "Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MitoticArrest_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", "Data from the assay component ATG_GRE_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GRE_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", "Data from the assay component LTEA_HepaRG_NFKB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NFKB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.", "Data from the assay component LTEA_HepaRG_BCL2L11 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BCL2L11, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_EGR1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EGR1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.", "Data from the assay component BSK_CASM3C_IL8 was analyzed into 1 assay endpoint. This assay endpoint, BSK_CASM3C_IL8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of binding reporter, gain or loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine intended target family, where the subfamily is interleukins.", "Data from the assay component LTEA_HepaRG_CDKN1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CDKN1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_LDH_cytotoxicity was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_LDH_cytotoxicity, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for loss-of-signal activity can be used to understand cell death. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is proliferation.", "Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_CellCycleArrest_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is arrest.", "The assay component endpoint  TOX21_CASP3_CHO was analyzed with bidirectional fitting relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity following chemical treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.", "Data from the assay component TOX21_ERb_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component LTEA_HepaRG_CFLAR was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CFLAR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_BID was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BID, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_HIF1A was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HIF1A, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.", "Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_p53Act_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of viability reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is tumor suppressor.", "Data from the assay component LTEA_HepaRG_XBP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_XBP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "Data from the assay component LTEA_HepaRG_ABCC3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ABCC3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transporter intended target family, where the subfamily is ABC transporter.", "Data from the assay component LTEA_HepaRG_ADK was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ADK, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the kinase intended target family, where the subfamily is steatosis.", "Data from the assay component LTEA_HepaRG_FAS was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FAS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cytokine receptor intended target family, where the subfamily is TNF receptor.", "Data from the assay component LTEA_HepaRG_FOXO1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_FOXO1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", "Data from the assay component ATG_E2F_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_E2F_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene E2F1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is E2F transcription factor.", "Data from the assay component OT_AR_ARELUC_AG_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_AR_ARELUC_AG_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene AR. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMembPot_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of membrane potential reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component LTEA_HepaRG_PPP2R4 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PPP2R4, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is serine/threonine phosphatase.", "Data from the assay component LTEA_HepaRG_ICAM1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_ICAM1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell adhesion molecules intended target family, where the subfamily is Immunoglobulin CAM.", "Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the baseline of activity. \r\n\r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.", "Data from the assay component LTEA_HepaRG_TGFB1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TGFB1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is transforming growth factor beta.", "Data from the assay component TOX21_NFkB_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_NFkB_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is NF-kappa B.", "Data from the assay component LTEA_HepaRG_SDHB was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_SDHB, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is ubiquinone.", "Data from the assay component ATG_Myb_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_Myb_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYB. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is MYB proteins.", "Data from the assay component APR_HepG2_MitoMass_72hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMass_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component LTEA_HepaRG_EZR was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EZR, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the membrane protein intended target family, where the subfamily is Cellular remodeling.", "Data from the assay component LTEA_HepaRG_MMP10 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_MMP10, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is matrix metalloproteinase.", "Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MicrotubuleCSK_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of conformation reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component TOX21_ELG1_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ELG1_LUC_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATAD5.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the hydrolase intended target family, where the subfamily is atpase.", "Data from the assay component LTEA_HepaRG_TGFA was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TGFA, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is EGF-like domain.", "Data from the assay component LTEA_HepaRG_BAX was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BAX, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component LTEA_HepaRG_EGF was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_EGF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is EGF-like domain.", "Data from the assay component LTEA_HepaRG_CASP3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CASP3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", "Data from the assay component ATG_FoxA2_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_FoxA2_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXA2. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is forkhead box protein.", "Data from the assay component ATG_GATA_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_GATA_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GATA1. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is GATA proteins.", "Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMass_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component LTEA_HepaRG_PTEN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_PTEN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the phosphatase intended target family, where the subfamily is dual-specific phosphatase.", "Data from the assay component ATG_STAT3_CIS was analyzed into 1 assay endpoint. \n\nThis assay endpoint, ATG_STAT3_CIS, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \n\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene STAT3. \n\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \n\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is stat protein.", "Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_FXR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component LTEA_HepaRG_JUN was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_JUN, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.", "Data from the assay component APR_HepG2_MicrotubuleCSK_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_MicrotubuleCSK_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of conformation reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the cellular-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is cell conformation.", "Data from the assay component LTEA_HepaRG_TIMP1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_TIMP1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease inhibitor intended target family, where the subfamily is metalloproteinase inhibitor.", "Data from the assay component LTEA_HepaRG_HGF was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_HGF, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor intended target family, where the subfamily is hepatocyte growth factor.", "Data from the assay component ATG_THRa1_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_THRa1_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ACEA_AR_agonist_80hr was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the geneAR \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component LTEA_HepaRG_KCNK1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_KCNK1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ion channel intended target family, where the subfamily is potassium channel.", "Data from the assay component LTEA_HepaRG_GSTM3 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_GSTM3, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where the subfamily is alkyl and aryl transferase.", "Data from the assay component LTEA_HepaRG_CASP8 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CASP8, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the protease intended target family, where the subfamily is cysteine protease.", "Data from the assay component ATG_RXRa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RXRa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component LTEA_HepaRG_NQO1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_NQO1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is quinone-acceptor.", "Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 1 assay endpoint. This assay endpoint, APR_HepG2_MitoMembPot_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of membrane potential reporter, gain or loss-of-signal activity can be used to understand changes in the signaling. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_StressKinase_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of enzyme reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is stress response.", "Data from the assay component TOX21_VDR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_VDR_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_PPARd_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_PPARd_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARD. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_LXRa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_GR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_GR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARa_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_LXRb_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_LXRb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component APR_HepG2_StressKinase_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_StressKinase_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of enzyme reporter, measures of protein for gain or loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is stress response.", "Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_VDR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_AR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_AR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.", "Data from the assay component TOX21_TSHR_HTRF_wt_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_wt_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.", "Data from the assay component APR_HepG2_NuclearSize_72hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_NuclearSize_72hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the nuclear-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component ATG_HNF4a_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_HNF4a_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4A. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 1 assay endpoint. \nThis assay endpoint, APR_HepG2_NuclearSize_24hr, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity. \nUsing a type of morphology reporter, measures of all nuclear dna for gain or loss-of-signal activity can be used to understand the signaling at the nuclear-level. \nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. \nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.", "Data from the assay component TOX21_SBE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Agonist_ratio, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.", "Data from the assay component LTEA_HepaRG_BAD was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_BAD, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is Cell proliferation, survival, death.", "Data from the assay component TOX21_SHH_3T3_GLI3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SHH_3T3_GLI3_Agonist, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene GLI3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function.", "Data from the assay component ATG_CAR_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_CAR_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component LTEA_HepaRG_CYP24A1 was analyzed into 1 endpoint. This assay endpoint, LTEA_HepaRG_CYP24A1, was analyzed with bidirectional fitting relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of mRNA induction for gain or loss-of-signal activity can be used to understand regulation of transcription factor activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is xenobiotic metabolism.", "Data from the assay component OT_PPARg_PPARgSRC1_1440 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_PPARg_PPARgSRC1_1440, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component OT_PPARg_PPARgSRC1_0480 was analyzed into 1 assay endpoint. \r\nThis assay endpoint, OT_PPARg_PPARgSRC1_0480, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\nUsing a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. \r\nFurthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. \r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_RARb_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RARb_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARB. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.", "Data from the assay component ATG_RORg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_RORg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORC. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.", "Data from the assay component ATG_ERRg_TRANS was analyzed into 1 assay endpoint. \r\n\r\nThis assay endpoint, ATG_ERRg_TRANS, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. \r\n\r\nUsing a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRG. \r\n\r\nFurthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. \r\n\r\nTo generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal."], "assay_function_type": ["agonist", "antagonist", "ratio", "reporter gene", "viability", "signaling", "inducer", "binding"], "normalized_data_type": ["percent_activity", "log2_fold_induction", "log10_fold_induction"], "burst_assay": [0, 1], "key_positive_control": ["46 uM rifampicin ", "1 nM T3", "RU486", "Rifampicin", "tetraoctylammonium bromide", "XCT790", "Cyclopamine", "Cyproterone acetate", "FCCP", "Beta-Naphthoflavone", "4-hydroxytamoxifen", "Nilutamide", "NA", "17b-Estradiol", "Letrozole", "Guggulsterone", "T0901317", "EGF", "Rosiglitazone", "TO-901317", "ER50891", "MG 132", "Mifeprostone", "Mitomycin C;Nutlin3", "CITCO", "GW9662", "PK11195", "Omeprazole", "6-formylindolo carbazole", null, "colchicine", "MK886", "R1881", "17-AAG", "Etoposide", "Trichostatin A", "9-cis-Retinoic acid", "1alpha,25-Dihydroxy vitamin D3", "Dexamethasone", "TSH", "Geldanamycin", "Forskolin", "4,5-alpha-Dihydrotestosterone", "DMSO", "Cobalt(II)chloride hexahydrate", "Camptothecin;Anisomycin;Paclitaxel;CCCP", "GW4064", "Staurosporine", "1 nM T293", "Genistein", "no TSH stimulation", "GW0742", "Retinol", "Isoproterenol;Fenoterol", "promegestone (R5020)", "L-165,041", "Paclitaxel;CCCP", "(Z)-4-Hydroxytamoxifen", "Camptothecin;Anisomycin", "TRH", "Chenodeoxycholic acid", "dihydroxytestosterone (DHT)", "6-alpha-Fluorotestosterone", "TNFa", "5-Fluorouridine", "CDCA", "T3", "testosterone", "Calcitriol", "GW7647", "Retinoic Acid", "1a,25-Dihydroxyvitamin D3", "6a-Fluorotestosterone", "TGFb", "SAG", "GW1929"], "signal_direction": ["gain", "loss", "bidirectional"], "intended_target_type": ["protein", "cellular", "pathway", "rna"], "intended_target_type_sub": ["receptor", "transcription factor", "cellular", "pathway-specified", "mitochondria", "enzyme", "mRNA", "protein-specified", "protein-unspecified", "miRNA", "nucleus"], "intended_target_family": ["nuclear receptor", "cell cycle", "dna binding", "cell morphology", "cyp", "growth factor receptor", "hydrolase", "cell adhesion molecules", "cytokine", "gpcr", "protease", "transferase", "transporter", "apoptosis", "protease inhibitor", "growth factor", "lyase", "kinase", "oxidoreductase", "filaments", "apolipoprotein", "misc protein", "esterase", "phosphatase", "oxidase", "catalase", "mutagenicity response", "cytokine receptor", "microrna", "ligase", "membrane protein", "ion channel"], "intended_target_family_sub": ["non-steroidal", "steroidal", "cytotoxicity", "orphan", "zinc finger", "organelle conformation", "basic leucine zipper", "steroidogenesis-related", "transforming growth factor beta", "tumor suppressor", "xenobiotic", "basic helix-loop-helix protein", "xenobiotic metabolism", "proliferation", "POU domain protein", "heat shock protein", "histone H2A", "basic helix-loop-helix leucine zipper", "NA", "MHC Class II", "interferon regulatory factors", "cell conformation", "chemotactic factor", "paired box protein", "selectins", "inflammatory factor", "collagen", "Smad protein", "HMG box protein", "thyrotropin-releasing hormone receptor", "Immunoglobulin CAM", "other cytokine", "colony stimulating factor", "plasmogen activator", "rhodopsin-like receptor", "plasmogen activator inhibitor", "matrix metalloproteinase", "interleukins", "glucuronosyltransferase", "NF-kappa B", "hypoxia-response element", "coagulation factor", "fatty acid carrier protein", "caspase", "metalloproteinase inhibitor", "insulin-like", "nuclear factor I", "HMG-CoA synthase", "ABC transporter", "serine protease", "serine/threonine kinase", "organic cation transporter", "NR mediated metabolism", "fatty acid synthase", "dioxygenase", "keratin", "sulfotransferase", "basic helix-turn-helix leucine zipper", "Steatosis", "LDL receptor", "lipase", "alkyl and aryl transferase", "Cell proliferation, survival, death", "steatosis", "nuclear respiratory factors", "apolipoproteins", "arrest", "receptor tyrosine kinase", "oxidative stress", "Oxidative Stress", "winged helix-turn-helix", "hormone carrier protein", "organic anion transporter", "cellular response to DNA damage stimulus", "stat protein", "JAK-STAT cytokine receptor", "post-transcriptional regulation", "C-N ligase", "TNF receptor", "forkhead box protein", "homeobox protein", "E2F transcription factor", "serine/threonine phosphatase", "ubiquinone", "MYB proteins", "Cellular remodeling", "atpase", "EGF-like domain", "cysteine protease", "GATA proteins", "dual-specific phosphatase", "hepatocyte growth factor", "potassium channel", "quinone-acceptor", "stress response"], "fit_all": [0], "cell_viability_assay": [0, 1], "data_usability": [1], "aid": [670, 327, 595, 5, 586, 581, 589, 311, 324, 372, 678, 592, 441, 587, 320, 593, 319, 585, 314, 588, 679, 376, 580, 6, 313, 579, 583, 452, 442, 578, 380, 321, 426, 450, 1, 377, 323, 594, 402, 451, 379, 328, 404, 672, 443, 374, 405, 640, 403, 371, 11, 534, 7, 378, 310, 407, 373, 582, 317, 381, 322, 533, 318, 425, 14, 375, 406, 8, 10, 575, 13, 9, 12, 312, 292, 681, 4, 304, 680, 671, 296, 291, 576, 305, 295, 298, 325, 297, 3, 306, 301, 302, 307, 294, 293, 290, 577, 309, 308], "assay_component_name": ["TOX21_PXR_agonist", "TOX21_TR_LUC_GH3_Antagonist", "TOX21_PR_BLA_Antagonist_ratio", "ATG_PXRE_CIS", "TOX21_RT_HEK293_GLO_40hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability", "TOX21_ERR_Antagonist", "TOX21_RT_HEK293_GLO_24hr_viability", "TOX21_SHH_3T3_GLI3_Antagonist", "TOX21_AR_BLA_Antagonist_ratio", "TOX21_MMP_ratio", "TOX21_ARE_BLA_Agonist_ratio", "TOX21_RT_HEK293_GLO_16hr_viability", "TOX21_CASP3_CHO_viability", "TOX21_ERb_BLA_Antagonist_ratio", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_TR_LUC_GH3_Antagonist_viability", "TOX21_PXR_viability", "TOX21_RT_HEPG2_FLO_40hr_viability", "TOX21_RT_HEK293_GLO_08hr_viability", "ATG_NRF2_ARE_CIS", "TOX21_SHH_3T3_GLI3_Antagonist_viability", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_RT_HEPG2_FLO_32hr_viability", "TOX21_ERb_BLA_Agonist_viability", "TOX21_ERa_BLA_Antagonist_ratio", "TOX21_PGC_ERR_Antagonist", "TOX21_RT_HEK293_FLO_40hr_viability", "TOX21_Aromatase_Inhibition", "TOX21_SHH_3T3_GLI3_Agonist_viability", "TOX21_ERb_BLA_Antagonist_viability", "TOX21_ERR_viability", "TOX21_SBE_BLA_Antagonist_ratio", "TOX21_Aromatase_Inhibition_viability", "TOX21_FXR_BLA_Antagonist_ratio", "TOX21_AR_BLA_Antagonist_viability", "TOX21_RT_HEPG2_FLO_24hr_viability", "TOX21_PGC_ERR_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "TOX21_RT_HEK293_FLO_32hr_viability", "ATG_PXR_TRANS", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_CAR_Antagonist_viability", "TOX21_HRE_BLA_Agonist_viability", "TOX21_AP1_BLA_Agonist_ratio", "TOX21_RXR_BLA_Agonist_viability", "TOX21_CAR_Agonist_viability", "TOX21_VDR_BLA_Agonist_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "ATG_PPARg_TRANS", "ATG_VDRE_CIS", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RAR_LUC_Antagonist", "ACEA_ER_AUC_viability", "TOX21_PPARd_BLA_Agonist_viability", "TOX21_RT_HEK293_FLO_24hr_viability", "ATG_ERE_CIS", "TOX21_RORg_LUC_CHO_Antagonist_viability", "TOX21_RT_HEPG2_GLO_16hr_viability", "TOX21_RT_HEPG2_GLO_24hr_viability", "TOX21_GR_BLA_Antagonist_ratio", "TOX21_RT_HEPG2_GLO_08hr_viability", "TOX21_PR_BLA_Antagonist_viability", "ATG_ERa_TRANS", "TOX21_PR_BLA_Agonist_viability", "TOX21_p53_BLA_p2_ratio", "TOX21_H2AX_HTRF_CHO_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", "TOX21_CAR_Agonist", "TOX21_PPARg_BLA_Antagonist_ratio", "TOX21_AhR_LUC_Agonist_viability", "TOX21_p53_BLA_p4_viability", "TOX21_RT_HEPG2_FLO_16hr_viability", "TOX21_p53_BLA_p4_ratio", "TOX21_CASP3_HEPG2_viability", "TOX21_CAR_Antagonist", "TOX21_RT_HEPG2_GLO_32hr_viability", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", "TOX21_p53_BLA_p1_ratio", "TOX21_AhR_LUC_Agonist", "ATG_MRE_CIS", "TOX21_p53_BLA_p5_ratio", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", "TOX21_p53_BLA_p3_ratio", "TOX21_RT_HEK293_FLO_16hr_viability", "TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", "ATG_DR4_LXR_CIS", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", "TOX21_ARE_BLA_agonist_viability", "TOX21_RT_HEPG2_GLO_40hr_viability", "ATG_Ahr_CIS", "ATG_AP_1_CIS", "TOX21_MMP_viability", "LTEA_HepaRG_CYP1A1", "BSK_hDFCGF_Proliferation", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", "TOX21_p53_BLA_p3_viability", "ATG_PPRE_CIS", "TOX21_GR_BLA_Antagonist_viability", "ACEA_AR_antagonist_80hr", "TOX21_p53_BLA_p2_viability", "BSK_3C_Proliferation", "TOX21_PPARd_BLA_Antagonist_viability", "TOX21_PPARd_BLA_Antagonist_ratio", "ACEA_AR_antagonist_AUC_viability", "TOX21_AR_BLA_Agonist_ratio", "TOX21_NFkB_BLA_agonist_viability", "ATG_HIF1a_CIS", "ATG_Oct_MLP_CIS", "TOX21_HSE_BLA_Agonist_ratio", "TOX21_RT_HEPG2_FLO_08hr_viability", "TOX21_H2AX_HTRF_CHO_Agonist_ratio", "LTEA_HepaRG_CYP2B6", "TOX21_FXR_BLA_Antagonist_viability", "TOX21_AP1_BLA_Agonist_viability", "TOX21_p53_BLA_p1_viability", "ATG_SREBP_CIS", "TOX21_HDAC_Inhibition", "TOX21_ELG1_LUC_Agonist_viability", "ATG_RXRb_TRANS", "BSK_3C_HLADR", "TOX21_VDR_BLA_Antagonist_viability", "TOX21_VDR_BLA_Antagonist_ratio", "ATG_EGR_CIS", "TOX21_GR_BLA_Agonist_ratio", "ACEA_AR_agonist_AUC_viability", "ATG_Xbp1_CIS", "TOX21_PPARg_BLA_Antagonist_viability", "LTEA_HepaRG_CYP1A2", "TOX21_ERa_BLA_Agonist_ratio", "ATG_ISRE_CIS", "ACEA_ER_80hr", "BSK_3C_SRB", "BSK_hDFCGF_IP10", "TOX21_RAR_LUC_Agonist_viability", "ATG_Pax6_CIS", "BSK_SAg_Eselectin", "BSK_SAg_CD40", "TOX21_FXR_BLA_agonist_viability", "TOX21_ESRE_BLA_viability", "BSK_4H_Eotaxin3", "BSK_hDFCGF_CollagenIII", "ATG_BRE_CIS", "BSK_CASM3C_Proliferation", "ATG_TCF_b_cat_CIS", "TOX21_TSHR_HTRF_Agonist_ratio", "BSK_hDFCGF_VCAM1", "BSK_SAg_CD38", "ATG_RORE_CIS", "ATG_PBREM_CIS", "BSK_hDFCGF_MCSF", "BSK_LPS_CD40", "BSK_SAg_CD69", "LTEA_HepaRG_CYP2E1", "BSK_LPS_VCAM1", "TOX21_p53_BLA_p5_viability", "ATG_HSE_CIS", "ATG_DR5_RAR_CIS", "BSK_4H_Pselectin", "BSK_4H_VCAM1", "TOX21_HSE_BLA_agonist_viability", "BSK_3C_uPAR", "BSK_BE3C_HLADR", "BSK_LPS_PGE2", "BSK_hDFCGF_PAI1", "BSK_KF3CT_MMP9", "BSK_LPS_TNFa", "BSK_SAg_IL8", "ATG_CRE_CIS", "LTEA_HepaRG_UGT1A1", "BSK_BE3C_IP10", "TOX21_AR_LUC_MDAKB2_Agonist", "ATG_p53_CIS", "OT_AR_ARSRC1_0960", "BSK_SAg_PBMCCytotoxicity", "BSK_3C_MCP1", "TOX21_RXR_BLA_Agonist_ratio", "ATG_IR1_CIS", "BSK_BE3C_MMP1", "BSK_LPS_MCSF", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", "ATG_NF_kB_CIS", "TOX21_HRE_BLA_Agonist_ratio", "BSK_hDFCGF_SRB", "BSK_3C_Eselectin", "BSK_3C_TissueFactor", "BSK_LPS_IL8", "ATG_Sp1_CIS", "BSK_4H_SRB", "LTEA_HepaRG_CYP2C19", "LTEA_HepaRG_CYP3A4", "ATG_E_Box_CIS", "BSK_4H_MCP1", "BSK_3C_IL8", "BSK_SAg_MCP1", "APR_HepG2_CellLoss_72hr", "BSK_4H_uPAR", "TOX21_ERa_BLA_Antagonist_viability", "BSK_LPS_SRB", "BSK_KF3CT_IP10", "BSK_hDFCGF_MMP1", "BSK_SAg_SRB", "LTEA_HepaRG_FABP1", "OT_FXR_FXRSRC1_0480", "BSK_3C_VCAM1", "BSK_hDFCGF_MIG", "TOX21_SBE_BLA_Agonist_viability", "TOX21_CASP3_HEPG2", "BSK_KF3CT_TIMP2", "BSK_CASM3C_VCAM1", "BSK_LPS_MCP1", "LTEA_HepaRG_CYP3A7", "BSK_BE3C_PAI1", "BSK_LPS_IL1a", "LTEA_HepaRG_CYP4A11", "BSK_LPS_Eselectin", "LTEA_HepaRG_CYP7A1", "BSK_KF3CT_IL1a", "BSK_CASM3C_Thrombomodulin", "TOX21_RAR_LUC_Antagonist_viability", "TOX21_SBE_BLA_Antagonist_viability", "TOX21_TRHR_HEK293_antagonist", "OT_ER_ERaERb_1440", "ATG_C_EBP_CIS", "LTEA_HepaRG_IGF1", "ATG_NFI_CIS", "LTEA_HepaRG_CYP4A22", "TOX21_PGC_ERR_Agonist", "OT_AR_ARSRC1_0480", "LTEA_HepaRG_HMGCS2", "BSK_BE3C_IL1a", "TOX21_TSHR_HTRF_Antagonist_ratio", "OT_FXR_FXRSRC1_1440", "LTEA_HepaRG_ABCB11", "BSK_hDFCGF_TIMP1", "BSK_LPS_TissueFactor", "BSK_CASM3C_HLADR", "BSK_BE3C_tPA", "TOX21_ESRE_BLA_ratio", "BSK_CASM3C_MCSF", "LTEA_HepaRG_PEG10", "BSK_KF3CT_MCP1", "LTEA_HepaRG_PDK4", "LTEA_HepaRG_SLC22A1", "ATG_PPARa_TRANS", "BSK_BE3C_uPA", "LTEA_HepaRG_ABCB1", "LTEA_HepaRG_THRSP", "LTEA_HepaRG_FASN", "TOX21_ERR_Agonist", "BSK_KF3CT_uPA", "BSK_CASM3C_uPAR", "TOX21_RAR_LUC_Agonist", "BSK_BE3C_uPAR", "OT_ER_ERaERb_0480", "LTEA_HepaRG_ABCC2", "OT_ER_ERbERb_1440", "TOX21_PPARg_BLA_Agonist_ratio", "ATG_Sox_CIS", "LTEA_HepaRG_CYP2C8", "OT_ER_ERbERb_0480", "BSK_CASM3C_IL6", "LTEA_HepaRG_FMO3", "BSK_CASM3C_MCP1", "LTEA_HepaRG_KRT19", "APR_HepG2_CellLoss_24hr", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", "OT_NURR1_NURR1RXRa_0480", "LTEA_HepaRG_SULT2A1", "ATG_AP_2_CIS", "LTEA_HepaRG_APOA5", "BSK_CASM3C_LDLR", "BSK_KF3CT_TGFb1", "BSK_KF3CT_ICAM1", "LTEA_HepaRG_LPL", "LTEA_HepaRG_GSTA2", "TOX21_PR_BLA_Agonist_ratio", "ATG_TGFb_CIS", "LTEA_HepaRG_ABCG2", "TOX21_PPARd_BLA_Agonist_ratio", "LTEA_HepaRG_LIPC", "BSK_CASM3C_SRB", "LTEA_HepaRG_ALPP", "LTEA_HepaRG_ACOX1", "ATG_NRF1_CIS", "BSK_CASM3C_SAA", "BSK_KF3CT_SRB", "BSK_CASM3C_TissueFactor", "ATG_Myc_CIS", "LTEA_HepaRG_DDIT3", "APR_HepG2_MitoticArrest_72hr", "BSK_4H_VEGFRII", "LTEA_HepaRG_CAT", "BSK_3C_Thrombomodulin", "BSK_SAg_MIG", "OT_ERa_GFPERaERE_0120", "LTEA_HepaRG_GADD45A", "BSK_BE3C_SRB", "ATG_Ets_CIS", "OT_ERa_GFPERaERE_0480", "LTEA_HepaRG_CYP2C9", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", "LTEA_HepaRG_IGFBP1", "LTEA_HepaRG_MYC", "OT_NURR1_NURR1RXRa_1440", "LTEA_HepaRG_GADD45G", "ATG_NURR1_TRANS", "BSK_3C_ICAM1", "LTEA_HepaRG_SLCO1B1", "LTEA_HepaRG_MMP3", "BSK_hDFCGF_IL8", "LTEA_HepaRG_UGT1A6", "APR_HepG2_P-H2AX_72hr", "ATG_GLI_CIS", "TOX21_TRHR_HEK293_agonist", "BSK_BE3C_MIG", "LTEA_HepaRG_STAT3", "LTEA_HepaRG_NFE2L2", "APR_HepG2_CellCycleArrest_72hr", "LTEA_HepaRG_IL6R", "LTEA_HepaRG_HSPA1A", "LTEA_HepaRG_ACLY", "LTEA_HepaRG_MIR122", "BSK_3C_MIG", "LTEA_HepaRG_GADD45B", "LTEA_HepaRG_GCLM", "BSK_hDFCGF_EGFR", "APR_HepG2_P-H2AX_24hr", "LTEA_HepaRG_TNFRSF1A", "LTEA_HepaRG_CYP3A5", "BSK_CASM3C_MIG", "LTEA_HepaRG_TP53", "ATG_FoxO_CIS", "TOX21_HDAC_Inhibition_viability", "BSK_BE3C_TGFb1", "LTEA_HepaRG_FOXO3", "OT_ER_ERaERa_1440", "OT_ER_ERaERa_0480", "ATG_HNF6_CIS", "TOX21_FXR_BLA_Agonist_ratio", "LTEA_HepaRG_BCL2", "LTEA_HepaRG_IL6", "APR_HepG2_p53Act_72hr", "LTEA_HepaRG_CCND1", "LTEA_HepaRG_GCLC", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "APR_HepG2_MitoticArrest_24hr", "ATG_GRE_CIS", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", "LTEA_HepaRG_NFKB1", "LTEA_HepaRG_BCL2L11", "LTEA_HepaRG_EGR1", "BSK_CASM3C_IL8", "LTEA_HepaRG_CDKN1A", "LTEA_HepaRG_LDH_cytotoxicity", "APR_HepG2_CellCycleArrest_24hr", "TOX21_CASP3_CHO", "TOX21_ERb_BLA_Agonist_ratio", "LTEA_HepaRG_CFLAR", "LTEA_HepaRG_BID", "LTEA_HepaRG_HIF1A", "APR_HepG2_p53Act_24hr", "LTEA_HepaRG_XBP1", "LTEA_HepaRG_ABCC3", "LTEA_HepaRG_ADK", "LTEA_HepaRG_FAS", "LTEA_HepaRG_FOXO1", "ATG_E2F_CIS", "OT_AR_ARELUC_AG_1440", "APR_HepG2_MitoMembPot_24hr", "LTEA_HepaRG_PPP2R4", "LTEA_HepaRG_ICAM1", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", "LTEA_HepaRG_TGFB1", "TOX21_NFkB_BLA_agonist_ratio", "LTEA_HepaRG_SDHB", "ATG_Myb_CIS", "APR_HepG2_MitoMass_72hr", "LTEA_HepaRG_EZR", "LTEA_HepaRG_MMP10", "APR_HepG2_MicrotubuleCSK_72hr", "TOX21_ELG1_LUC_Agonist", "LTEA_HepaRG_TGFA", "LTEA_HepaRG_BAX", "LTEA_HepaRG_EGF", "LTEA_HepaRG_CASP3", "ATG_FoxA2_CIS", "ATG_GATA_CIS", "APR_HepG2_MitoMass_24hr", "LTEA_HepaRG_PTEN", "ATG_STAT3_CIS", "ATG_FXR_TRANS", "LTEA_HepaRG_JUN", "APR_HepG2_MicrotubuleCSK_24hr", "LTEA_HepaRG_TIMP1", "LTEA_HepaRG_HGF", "ATG_THRa1_TRANS", "ACEA_AR_agonist_80hr", "LTEA_HepaRG_KCNK1", "LTEA_HepaRG_GSTM3", "LTEA_HepaRG_CASP8", "ATG_RXRa_TRANS", "LTEA_HepaRG_NQO1", "APR_HepG2_MitoMembPot_72hr", "APR_HepG2_StressKinase_72hr", "TOX21_VDR_BLA_Agonist_ratio", "ATG_PPARd_TRANS", "ATG_LXRa_TRANS", "ATG_GR_TRANS", "ATG_RARa_TRANS", "ATG_LXRb_TRANS", "APR_HepG2_StressKinase_24hr", "ATG_RARg_TRANS", "ATG_VDR_TRANS", "ATG_AR_TRANS", "TOX21_TSHR_wt_Agonist_HTRF_ratio", "APR_HepG2_NuclearSize_72hr", "ATG_HNF4a_TRANS", "APR_HepG2_NuclearSize_24hr", "TOX21_SBE_BLA_Agonist_ratio", "LTEA_HepaRG_BAD", "TOX21_SHH_3T3_GLI3_Agonist", "ATG_CAR_TRANS", "LTEA_HepaRG_CYP24A1", "OT_PPARg_PPARgSRC1_1440", "OT_PPARg_PPARgSRC1_0480", "ATG_RARb_TRANS", "ATG_RORg_TRANS", "ATG_ERRg_TRANS"], "assay_component_desc": ["TOX21_PXR_agonist is one of one assay component(s) measured or calculated from the TOX21_PXR  assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_TR_LUC_GH3_Antagonist is one of one assay component(s) measured or calculated from the TOX21_TR_LUC_GH3_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_PR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "ATG_PXRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_RT_HEK293_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEK293_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_RT_HEK293_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_SHH_3T3_GLI3_Antagonist is one of one assay component(s) measured or calculated from the TOX21_SHH_3T3_GLI3_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_AR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_MMP_ratio is one of 2 assay component(s) measured or calculated from the TOX21_MMP assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by homogenous mitochondrial membrane potential assay technology.", "TOX21_ARE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_RT_HEK293_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_CASP3_CHO_viability is a component of the TOX21_CASP3_CHO assay. This component measures cell viability using the CellTiter-Fluor assay system.", "TOX21_ERb_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals following addition of luciferin substrate and ATP.", "TOX21_TR_LUC_GH3_Antagonist_viability is an assay readout measuring viability via receptor activity and designed using bioluminescence signals detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_PXR_viability is a component of the TOX21_PXR assay. This component measures cell viability using the CellTiter-Fluor assay system.", "TOX21_RT_HepG2_FLO_40hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure", "TOX21_RT_HEK293_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "ATG_NRF2_ARE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_SHH_3T3_GLI3_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERa_LUC_VM7_Agonist is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_RT_HepG2_FLO_32hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure", "TOX21_ERb_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERa_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_PGC_ERR_Antagonist is one of one assay component(s) measured or calculated from the TOX21_PGC_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "TOX21_RT_HEK293_FLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 40 hr after exposure", "TOX21_Aromatase_Inhibition is one of one assay component(s) measured or calculated from the TOX21_Aromatase_Inhibition assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_SHH_3T3_GLI3_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERb_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_SBE_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_Aromatase_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_FXR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_AR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RT_HepG2_FLO_24hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure", "TOX21_PGC_ERR_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_RT_HEK293_FLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 32 hr after exposure", "ATG_PXR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_CAR_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_HRE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_AP1_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "TOX21_RXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_CAR_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_VDR_BLA_Agonist_viability is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Agonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "ATG_PPARg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_VDRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_RORg_LUC_CHO_Antagonist is one of one assay component(s) measured or calculated from the TOX21_RORg_LUC_CHO_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "TOX21_RAR_LUC_Antagonist is one of one assay component(s) measured or calculated from the TOX21_RAR_LUC_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "ACEA_ER_AUC_viability is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "TOX21_PPARd_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RT_HEK293_FLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 24 hr after exposure", "ATG_ERE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_RORg_LUC_CHO_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RT_HEPG2_GLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_RT_HEPG2_GLO_24hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_GR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_RT_HEPG2_GLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_PR_BLA_Antagonist_viability is a component of the TOX21_PR_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_ERa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_PR_BLA_Agonist_viability is a component of the TOX21_PR_BLA_Agonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p2_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_H2AX_HTRF_CHO_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_CAR_Agonist is one of one assay component(s) measured or calculated from the TOX21_CAR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_PPARg_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_AhR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p4_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RT_HepG2_FLO_16hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure", "TOX21_p53_BLA_p4_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1)reporter gene substrate used as the measure of target activity.", "TOX21_CASP3_HEPG2_viability is a component of the TOX21_CASP3_HEPG2 assay. This component measures cell viability using the CellTiter-Fluor assay system.", "TOX21_CAR_Antagonist is one of one assay component(s) measured or calculated from the TOX21_CAR_Antagonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_RT_HEPG2_GLO_32hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p1_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_AhR_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_AhR_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CALUX luciferase quantitation technology.", "ATG_MRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_p53_BLA_p5_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p3_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "TOX21_RT_HEK293_FLO_16hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 16 hr after exposure", "TOX21_RT_HEK293_FLO_08hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEK293_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_DR4_LXR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ARE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_RT_HEPG2_GLO_40hr_viability is one of one assay component(s) measured or calculated from the TOX21_RT_HEPG2_GLO_00hr_viability assay. It is designed to make measurements of viable cells as detected with bioluminescence signal generated by NanoLuc luciferase catalysis of a profurimazine substrate which require intracellular reduction of the substrate in a viable cell. ", "ATG_Ahr_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_AP_1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_MMP_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "LTEA_HepaRG_CYP1A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "BSK_hDFCGF_Proliferation is an assay component measured in the BSK_hDFCGF assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p3_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_PPRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_GR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ACEA_AR_antagonist_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "TOX21_p53_BLA_p2_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "BSK_3C_Proliferation is an assay component measured in the BSK_3C assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", "TOX21_PPARd_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_PPARd_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "ACEA_AR_80hr is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "TOX21_AR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity. ", "TOX21_NFkB_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_HIF1a_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_Oct_MLP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_HSE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene  substrate used as the measure of target activity", "TOX21_RT_HepG2_FLO_08hr_viability is one of one assay component(s) measured or calculated from theTOX21_RT_HepG2_FLO_00hr_viability. It is designed to make measurements of dead cells as detected with biofluorescent emission of fluorescent dye bound to dead cell DNA at 8 hr after exposure", "TOX21_H2AX_HTRF_CHO_Agonist_ratio is an assay readout measuring protein phosphorylation and designed using homogenous time resolved fluorescence between two labled antibodies. The signal is derived from the  the ratio of acceptor (d2)-conjugated antibody emission (ch2) to donor (Europium-cryptate)-conjugated antibody emission (ch1) used as the measure of target activity. ", "LTEA_HepaRG_CYP2B6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "TOX21_FXR_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_AP1_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_p53_BLA_p1_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_SREBP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_HDAC_Inhibition is one of one assay component(s) measured or calculated from the TOX21_HDAC_Inhibition assay. It is designed to make measurements of HDAC activity as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_ELG1_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_RXRb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_3C_HLADR is an assay component measured in the BSK_3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", "TOX21_VDR_BLA_Antagonist_viability is one of 2 assay component(s) measured or calculated from the TOX21_VDR_BLA_Antagonist assay. It is designed to make measurements of ATP content, a form of viability reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_VDR_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene reporter gene substrate used as the measure of target activity.", "ATG_EGR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_GR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity.", "ACEA_AR_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "ATG_Xbp1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_PPARg_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "LTEA_HepaRG_CYP1A2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "TOX21_ERa_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) substrate used as the measure of target activity.", "ATG_ISRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ACEA_ER_80hr is one of two assay component(s) measured or calculated from the ACEA_ER assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "BSK_3C_SRB is an assay component measured in the BSK_3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_hDFCGF_IP10 is an assay component measured in the BSK_hDFCGF assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", "TOX21_RAR_LUC_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_Pax6_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_SAg_Eselectin is an assay component measured in the BSK_SAg assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_CD40 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", "TOX21_FXR_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_ESRE_BLA_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "BSK_4H_Eotaxin3 is an assay component measured in the BSK_4H assay. It measures Eotaxin-3 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_CollagenIII is an assay component measured in the BSK_hDFCGF assay. It measures Collagen antibody related to regulation of gene expression using ELISA technology.", "ATG_BRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_CASM3C_Proliferation is an assay component measured in the BSK_CASM3C assay. It measures 0.1% sulforhodamine related to cell proliferation using Sulforhodamine staining technology.", "ATG_TCF_b_cat_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_TSHR_HTRF_Agonist_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_HTRF_Agonist assay. It is designed to make measurements of TSHR agonism, with cAMP as an indicator of TSHR activation.", "BSK_hDFCGF_VCAM1 is an assay component measured in the BSK_hDFCGF assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_CD38 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", "ATG_RORE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_PBREM_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_hDFCGF_MCSF is an assay component measured in the BSK_hDFCGF assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_CD40 is an assay component measured in the BSK_LPS assay. It measures CD40 antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_CD69 is one of 10 assay component(s) measured or calculated from the BSK_SAg assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.", "LTEA_HepaRG_CYP2E1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "BSK_LPS_VCAM1 is an assay component measured in the BSK_LPS assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "TOX21_p53_BLA_p5_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "ATG_HSE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_DR5_RAR_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_4H_Pselectin is an assay component measured in the BSK_4H assay. It measures P-Selectin antibody related to regulation of gene expression using ELISA technology.", "BSK_4H_VCAM1 is an assay component measured in the BSK_4H assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "TOX21_HSE_BLA_Agonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "BSK_3CAR is an assay component measured in the BSK_3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_HLADR is an assay component measured in the BSK_BE3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_PGE2 is an assay component measured in the BSK_LPS assay. It measures PGE2 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_PAI1 is an assay component measured in the BSK_hDFCGF assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_MMP9 is an assay component measured in the BSK_KF3CT assay. It measures MMP-9 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_TNFa is an assay component measured in the BSK_LPS assay. It measures TNF-a antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_IL8 is an assay component measured in the BSK_SAg assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "ATG_CRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_UGT1A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated metabolism.", "BSK_BE3C_IP10 is an assay component measured in the BSK_BE3C assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", "TOX21_AR_LUC_MDAKB2_Agonist is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAkb2_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "ATG_p53_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "OT_AR_ARSRC1_0960 is one of one assay component(s) measured or calculated from the OT_AR_ARSRC1_0960 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "BSK_SAg_PBMCCytotoxicity is an assay component measured in the BSK_SAg assay. It measures Alamar blue related to cell death using Alamar Blue Reduction technology.", "BSK_3C_MCP1 is an assay component measured in the BSK_3C assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "TOX21_RXR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "ATG_IR1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_BE3C_MMP1 is an assay component measured in the BSK_BE3C assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_MCSF is an assay component measured in the BSK_LPS assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of red fluorescence localized in the nucleolar region of the cell nucleus as detected with high-content fluorescent imaging.", "ATG_NF_kB_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_HRE_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "BSK_hDFCGF_SRB is an assay component measured in the BSK_hDFCGF assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_3C_Eselectin is an assay component measured in the BSK_3C assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_TissueFactor is an assay component measured in the BSK_3C assay. It measures Tissue Factor antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_IL8 is an assay component measured in the BSK_LPS assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "ATG_Sp1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_4H_SRB is an assay component measured in the BSK_4H assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "LTEA_HepaRG_CYP2C19 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "LTEA_HepaRG_CYP3A4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "ATG_E_Box_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_4H_MCP1 is an assay component measured in the BSK_4H assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_3C_IL8 is an assay component measured in the BSK_3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_MCP1 is an assay component measured in the BSK_SAg assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "APR_HepG2_CellLoss_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "BSK_4HAR is an assay component measured in the BSK_4H assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", "TOX21_ERa_BLA_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "BSK_LPS_SRB is an assay component measured in the BSK_LPS assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_KF3CT_IP10 is an assay component measured in the BSK_KF3CT assay. It measures IP-10 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_MMP1 is an assay component measured in the BSK_hDFCGF assay. It measures MMP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_SRB is an assay component measured in the BSK_SAg assay. It measures protein content, a form of viability reporter, as detected with absorbance signals by Sulforhodamine staining technology.", "LTEA_HepaRG_FABP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "OT_FXR_FXRSRC1_0480 is one of one assay component(s) measured or calculated from the OT_FXR_FXRSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "BSK_3C_VCAM1 is an assay component measured in the BSK_3C assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_hDFCGF_MIG is an assay component measured in the BSK_hDFCGF assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "TOX21_SBE_BLA_Agonist_viability is a component of the TOX21_SBE_BLA_Agonist assay. This component measures cell viability using CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "TOX21_CASP3_HEPG2 is a component of the TOX21_CASP3_HEPG2 assay. This component measures caspase activity using the Caspase-Glo 3/7 assay system.", "BSK_KF3CT_TIMP2 is an assay component measured in the BSK_KF3CT assay. It measures TIMP-2 antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_VCAM1 is an assay component measured in the BSK_CASM3C assay. It measures VCAM-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_MCP1 is an assay component measured in the BSK_LPS assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_CYP3A7 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism/Undifferentiated hepatocyte.", "BSK_BE3C_PAI1 is an assay component measured in the BSK_BE3C assay. It measures PAI-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_IL1a is an assay component measured in the BSK_LPS assay. It measures IL-a antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_CYP4A11 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "BSK_LPS_Eselectin is an assay component measured in the BSK_LPS assay. It measures E-selectin antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_CYP7A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "BSK_KF3CT_IL1a is an assay component measured in the BSK_KF3CT assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_Thrombomodulin is an assay component measured in the BSK_CASM3C assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", "TOX21_RAR_LUC_Antagonist_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_SBE_BLA_Antagonist_viability is a component of the TOX21_SBE_BLA_Antagonist assay. This component measures cell viability using the CellTiter-Glo Luciferase-coupled ATP quantitation.", "TOX21_TRHR_HEK293_Antagonist is one of 2 assay components measured in the TOX21_TRHR_HEK293 assay. It is designed to make measurements of intracellular calcium, a form of biochemical reporter, as detected with Fluorescence intensity signals by FDSS 7000EX kinetic plate reader technology.", "OT_ER_ERaERb_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "ATG_C_EBP_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_IGF1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "ATG_NFI_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_CYP4A22 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "TOX21_PGC_ERR_Agonist is one of one assay component(s) measured or calculated from the TOX21_PGC_ERR_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "OT_AR_ARSRC1_0480 is one of one assay component(s) measured or calculated from the OT_AR_ARSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "LTEA_HepaRG_HMGCS2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "BSK_BE3C_IL1a is an assay component measured in the BSK_BE3C assay. It measures IL-1a antibody related to regulation of gene expression using ELISA technology.", "TOX21_TSHR_HTRF_Antagonist_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_Antagonist assay. It is designed to make measurements of TSHR antagonism, with cAMP as an indicator of TSHR activation.", "OT_FXR_FXRSRC1_1440 is one of one assay component(s) measured or calculated from the OT_FXR_FXRSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "LTEA_HepaRG_ABCB11  is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", "BSK_hDFCGF_TIMP1 is an assay component measured in the BSK_hDFCGF assay. It measures TIMP-1 antibody related to regulation of gene expression using ELISA technology.", "BSK_LPS_TissueFactor is an assay component measured in the BSK_LPS assay. It measures CD142 Tissue Factor antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3C_HLADR is an assay component measured in the BSK_CASM3C assay. It measures HLA-DR antibody related to regulation of gene expression using ELISA technology.", "BSK_BE3C_tPA is an assay component measured in the BSK_BE3C assay. It measures tPA antibody related to regulation of gene expression using ELISA technology.", "TOX21_ESRE_BLA_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "BSK_CASM3C_MCSF is an assay component measured in the BSK_CASM3C assay. It measures M-CSF antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_PEG10 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "BSK_KF3CT_MCP1 is an assay component measured in the BSK_KF3CT assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_PDK4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with PDK4 include\u00c2\u00a0Platelet Glycoprotein Iv Deficiency\u00c2\u00a0and\u00c2\u00a0Diabetes Mellitus, Noninsulin-Dependent.\u00c2\u00a0.", "LTEA_HepaRG_SLC22A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", "ATG_PPARa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_BE3CA is an assay component measured in the BSK_BE3C assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_ABCB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", "LTEA_HepaRG_THRSP is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "LTEA_HepaRG_FASN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "BSK_KF3CTA is an assay component measured in the BSK_KF3CT assay. It measures uPA antibody related to regulation of gene expression using ELISA technology.", "BSK_CASM3CAR is an assay component measured in the BSK_CASM3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", "TOX21_RAR_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_RAR_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology", "BSK_BE3CAR is an assay component measured in the BSK_BE3C assay. It measures uPAR antibody related to regulation of gene expression using ELISA technology.", "OT_ER_ERaERb_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERaERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "LTEA_HepaRG_ABCC2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", "OT_ER_ERbERb_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERbERb_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "TOX21_PPARg_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity..", "ATG_Sox_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_CYP2C8 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "OT_ER_ERbERb_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERbERb_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "BSK_CASM3C_IL6 is an assay component measured in the BSK_CASM3C assay. It measures IL-6 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_FMO3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "BSK_CASM3C_MCP1 is an assay component measured in the BSK_CASM3C assay. It measures MCP-1 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_KRT19 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "APR_HepG2_CellLoss_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell number, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is one of one assay component(s) measured or calculated from the TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signal following addition of luciferin substrate and ATP.", "OT_NURR1_NURR1RXRa_0480 is one of one assay component(s) measured or calculated from the OT_NURR1_NURR1RXRa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "LTEA_HepaRG_SULT2A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", "ATG_AP_2_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_APOA5 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "BSK_CASM3C_LDLR is an assay component measured in the BSK_CASM3C assay. It measures LDLR antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_TGFb1 is an assay component measured in the BSK_KF3CT assay. It measures TGF-b1 antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_ICAM1 is an assay component measured in the BSK_KF3CT assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_LPL is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "LTEA_HepaRG_GSTA2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", "TOX21_PR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "ATG_TGFb_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_ABCG2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis/NR mediated transport.", "TOX21_PPARd_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "LTEA_HepaRG_LIPC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "BSK_CASM3C_SRB is an assay component measured in the BSK_CASM3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "LTEA_HepaRG_ALPP is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_ACOX1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "ATG_NRF1_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_CASM3C_SAA is an assay component measured in the BSK_CASM3C assay. It measures SAA antibody related to regulation of gene expression using ELISA technology.", "BSK_KF3CT_SRB is an assay component measured in the BSK_KF3CT assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "BSK_CASM3C_TissueFactor is an assay component measured in the BSK_CASM3C assay. It measures Tissue Factor antibody related to regulation of gene expression using ELISA technology.", "ATG_Myc_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_DDIT3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", "APR_HepG2_MitoticArrest_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "BSK_4H_VEGFRII is an assay component measured in the BSK_4H assay. It measures VEGFRII antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_CAT is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", "BSK_3C_Thrombomodulin is an assay component measured in the BSK_3C assay. It measures Thrombomodulin antibody related to regulation of gene expression using ELISA technology.", "BSK_SAg_MIG is an assay component measured in the BSK_SAg assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "OT_ERa_GFPERaERE_0120 is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0120 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology.", "LTEA_HepaRG_GADD45A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", "BSK_BE3C_SRB is an assay component measured in the BSK_BE3C assay. It measures 0.1% sulforhodamine related to cell death using Sulforhodamine staining technology.", "ATG_Ets_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "OT_ERa_GFPERaERE_0480 is one of one assay component(s) measured or calculated from the OT_ERa_GFPERaERE_0480 assay. It is designed to make measurements of fluorescent protein induction, a form of inducible reporter, as detected with optical microscopy: fluorescence microscopy signals by Microscopy technology.", "LTEA_HepaRG_CYP2C9 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of the ratio of red fluorescence localized in the nucleolar region of the cell nucleus to red fluorescence localized in the cytoplasm as detected with high-content fluorescent imaging.", "LTEA_HepaRG_IGFBP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_MYC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "OT_NURR1_NURR1RXRa_1440 is one of one assay component(s) measured or calculated from the OT_NURR1_NURR1RXRa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "LTEA_HepaRG_GADD45G is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "ATG_NURR1_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "BSK_3C_ICAM1 is an assay component measured in the BSK_3C assay. It measures ICAM-1 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_SLCO1B1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", "LTEA_HepaRG_MMP3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", "BSK_hDFCGF_IL8 is an assay component measured in the BSK_hDFCGF assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_UGT1A6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "APR_HepG2_P-H2AX_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "ATG_GLI_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_TRHR_HEK293_Agonist is one of 2 assay components measured in the TOX21_TRHR_HEK293 assay. It is designed to make measurements of intracellular calcium, a form of biochemical reporter, as detected with Fluorescence intensity signals by FDSS 7000EX kinetic plate reader technology.", "BSK_BE3C_MIG is an assay component measured in the BSK_BE3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_STAT3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_NFE2L2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation/injury.", "APR_HepG2_CellCycleArrest_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "LTEA_HepaRG_IL6R is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.", "LTEA_HepaRG_HSPA1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", "LTEA_HepaRG_ACLY is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "LTEA_HepaRG_MIR122 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of MicroRNA.", "BSK_3C_MIG is an assay component measured in the BSK_3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_GADD45B is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_GCLM is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "BSK_hDFCGF_EGFR is an assay component measured in the BSK_hDFCGF assay. It measures EGFR antibody related to regulation of gene expression using ELISA technology.", "APR_HepG2_P-H2AX_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "LTEA_HepaRG_TNFRSF1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_CYP3A5 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "BSK_CASM3C_MIG is an assay component measured in the BSK_CASM3C assay. It measures MIG antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_TP53 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", "ATG_FoxO_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_HDAC_Inhibition_viability is an assay readout measuring cellular ATP content and detected with CellTiter-Glo Luciferase-coupled ATP quantitation.", "BSK_BE3C_TGFb1 is an assay component measured in the BSK_BE3C assay. It measures TGF-b1 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_FOXO3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "OT_ER_ERaERa_1440 is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_ER_ERaERa_0480 is one of one assay component(s) measured or calculated from the OT_ER_ERaERa_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "ATG_HNF6_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_FXR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "LTEA_HepaRG_BCL2 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_IL6 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Inflammation.", "APR_HepG2_p53Act_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "LTEA_HepaRG_CCND1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_GCLC is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is one of one assay component(s) measured or calculated from the TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "APR_HepG2_MitoticArrest_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "ATG_GRE_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of red fluorescence localized in the nucleolar region of the cell nucleus as detected with high-content fluorescent imaging.", "LTEA_HepaRG_NFKB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_BCL2L11 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_EGR1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "BSK_CASM3C_IL8 is an assay component measured in the BSK_CASM3C assay. It measures IL-8 antibody related to regulation of gene expression using ELISA technology.", "LTEA_HepaRG_CDKN1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_LDH_cytotoxicity is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of cell viability / cytotoxicity.", "APR_HepG2_CellCycleArrest_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "TOX21_CASP3_CHO is a component of the TOX21_CASP3_CHO assay. This component measures caspase activity using the Caspase-Glo 3/7 assay system.", "TOX21_ERb_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity. ", "LTEA_HepaRG_CFLAR is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_BID is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_HIF1A is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "APR_HepG2_p53Act_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dna content, a form of viability reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "LTEA_HepaRG_XBP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with XBP1 include\u00c2\u00a0Major Affective Disorder 7\u00c2\u00a0and\u00c2\u00a0Bipolar Disorde.", "LTEA_HepaRG_ABCC3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated transport.", "LTEA_HepaRG_ADK is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.", "LTEA_HepaRG_FAS is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_FOXO1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "ATG_E2F_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "OT_AR_ARELUC_AG_1440 is one of one assay component(s) measured or calculated from the OT_AR_ARELUC_AG_1440 assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by Luciferase technology.", "APR_HepG2_MitoMembPot_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "LTEA_HepaRG_PPP2R4 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_ICAM1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist is one of four assay components measured from the UPITT_AR_TIF2_PPIB assay. It is designed to make measurements of the ratio of red fluorescence localized in the nucleolar region of the cell nucleus to red fluorescence localized in the cytoplasm as detected with high-content fluorescent imaging.", "LTEA_HepaRG_TGFB1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "TOX21_NFkB_BLA_Agonist_ratio is an assay readout measuring reporter gene via transcription factor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "LTEA_HepaRG_SDHB is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "ATG_Myb_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "APR_HepG2_MitoMass_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "LTEA_HepaRG_EZR is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cellular remodeling.", "LTEA_HepaRG_MMP10 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.", "APR_HepG2_MicrotubuleCSK_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of protein conformation, a form of conformation reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "TOX21_ELG1_LUC_Agonist is one of one assay component(s) measured or calculated from the TOX21_ELG1_LUC_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "LTEA_HepaRG_TGFA is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_BAX is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_EGF is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_CASP3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "ATG_FoxA2_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_GATA_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "APR_HepG2_MitoMass_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "LTEA_HepaRG_PTEN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "ATG_STAT3_CIS is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_FXR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_JUN is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "APR_HepG2_MicrotubuleCSK_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of protein conformation, a form of conformation reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "LTEA_HepaRG_TIMP1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "LTEA_HepaRG_HGF is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "ATG_THRa1_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ACEA_AR_agonist_80hr is one of two assay component(s) measured or calculated from the ACEA_AR assay. It is designed to make measurements of real-time cell-growth kinetics, a form of growth reporter, as detected with electrical impedance signals by Real-Time Cell Electrode Sensor (RT-CES) technology.", "LTEA_HepaRG_KCNK1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Hyperplasia.", "LTEA_HepaRG_GSTM3 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Oxidative Stress.", "LTEA_HepaRG_CASP8 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "ATG_RXRa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_NQO1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Diseases associated with NQO1 include\u00c2\u00a0Tardive Dyskinesia\u00c2\u00a0and\u00c2\u00a0Childhood Leukemia.\u00c2\u00a0.", "APR_HepG2_MitoMembPot_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of dye binding, a form of membrane potential reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "APR_HepG2_StressKinase_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "TOX21_VDR_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "ATG_PPARd_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_LXRa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_GR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RARa_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_LXRb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "APR_HepG2_StressKinase_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "ATG_RARg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_VDR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_AR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "TOX21_TSHR_wt_Agonist_HTRF_ratio is one of one assay component(s) measured or calculated from the TOX21_TSHR_wt assay. It is designed to indicate background cAMP activity.", "APR_HepG2_NuclearSize_72hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_72hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "ATG_HNF4a_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "APR_HepG2_NuclearSize_24hr is one of 10 assay component(s) measured or calculated from the APR_HepG2_24hr assay. It is designed to make measurements of cell phenotype, a form of morphology reporter, as detected with fluorescence intensity signals by HCS Fluorescent Imaging technology.", "TOX21_SBE_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.", "LTEA_HepaRG_BAD is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Cell proliferation, survival, death.", "TOX21_SHH_3T3_GLI3_Agonist is one of one assay component(s) measured or calculated from the TOX21_SHH_3T3_GLI3_Agonist assay. It is designed to make measurements of luciferase induction, a form of inducible reporter, as detected with bioluminescence signals by CellTiter-Glo Luciferase-coupled ATP quantitation technology.", "ATG_CAR_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "LTEA_HepaRG_CYP24A1 is one of 102 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of NR mediated metabolism.", "OT_PPARg_PPARgSRC1_1440 is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_1440 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "OT_PPARg_PPARgSRC1_0480 is one of one assay component(s) measured or calculated from the OT_PPARg_PPARgSRC1_0480 assay. It is designed to make measurements of protein fragment complementation, a form of binding reporter, as detected with fluorescence intensity signals by Protein-fragment Complementation technology.", "ATG_RARb_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_RORg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.", "ATG_ERRg_TRANS is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology."], "assay_component_target_desc": ["The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction.\u00a0", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis.", "Progesterone receptor (PR), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. It is activated by the steroid hormone progesterone. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like PR causes disruption of normal endocrine function. ", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", "TOX21_RT_HEK293_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEK293_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|.", "TOX21_RT_HEK293_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_SHH_3T3_GLI3_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonism  of Gli3 activation using conditioned medium, part of the sonic hedgehog (Shh) pathway", "TOX21_AR_BLA_Antagonist_ratio was designed to  target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate ", "Mito-MPS is used as a stain for the membrane potential of the mitochondria.", "TOX21_ARE_BLA_Agonist_ratio was designed to  target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone", "TOX21_RT_HEK293_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection.", "TOX21_ERb_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 4-hydroxytamoxifen", "Androgen receptor (AR) is an important member of the nuclear receptor family. Its signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to develop methods to study and screen for the environmental chemicals that have the potential to interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system.", "The human pregnane X receptor (hPXR) regulates the expression of several drug metabolizing enzymes and induction of these proteins is a major mechanism for developing drug resistance in cancer. One such key enzyme catalyzing the drug metabolism is cytochrome P450 3A4 (CYP3A4). Changes in CYP3A4 expression affect drug metabolism, thereby reducing the therapeutic efficacy and altering toxicological response to a drug and which finally causes adverse drug interaction.", "TOX21_RT_HepG2_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HEK293_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ARE, which is responsive to the endogenous human nuclear factor, erythroid 2-like 2 [GeneSymbol:NFE2L2 | GeneID:4780 | Uniprot_SwissProt_Accession:Q16236].", "TOX21_ERa_LUC_VM7_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "TOX21_RT_HepG2_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_ERa_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen", "TOX21_PGC_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101|in the presence of PGC1a expression", "TOX21_RT_HEK293_FLO_40hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to modulation of the human cytochrome P450, family 19, subfamily A, polypeptide 1 [GeneSymbol:CYP19A1 | GeneID:1588 | Uniprot_SwissProt_Accession:P11511].", "Transforming growth factor beta (TGF-beta) superfamily consists of a large number of structurally related dimeric proteins that act as hormones or local mediators in regulating a wide range of biological functions. This superfamily includes TGF-betas themselves, the bone morphogenetic proteins (BMPs) and the activins. These ligands induce oligomerization of serine/threonine receptor kinases and phosphorylate the cytoplasmic signaling molecules of Smad protein family.", "TOX21_FXR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone", "TOX21_RT_HepG2_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "TOX21_RT_HEK293_FLO_32hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PXR, also known as human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469].", "Androgen receptor (AR) is an important member of the nuclear receptor family. Its signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to develop methods to study and screen for the environmental chemicals that have the potential to interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. Therefore AR binding assay for screening androgen antagonists can be used to identify potential endocrine disruptors. Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "TOX21_AP1_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to JUN gene(s) using a positive control of EGF", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372] using a positive control of 4-hydroxytamoxifen", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARg, also known as human peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARG | GeneID:5468 | Uniprot_SwissProt_Accession:P37231].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element VDRE, which is responsive to the endogenous human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473].", "TOX21_RORg_LUC_CHO_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoid-related orphan receptor gamma  [GeneSymbol:NR1F3]", "TOX21_RAR_LUC_Antagonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoic acid receptor alpha  [GeneSymbol:RARA]", "Electrical impedance is used to quantify changes to the growth of the cells where increase impedance is positively correlated with increased cell growth", "TOX21_RT_HEK293_FLO_24hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ERE, which is responsive to the endogenous human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "TOX21_RT_HEPG2_GLO_16hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_RT_HEPG2_GLO_24hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_GR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone", "TOX21_RT_HEPG2_GLO_08hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERa, also known as human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "TOX21_p53_BLA_p2_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "TOX21_CAR_Agonist assay  was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human constitutive androstane receptor (CAR) [GeneSymbol:NR1I3]", "TOX21_PPARg_BLA_Antagonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662", "TOX21_RT_HepG2_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_p53_BLA_p4_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "Apoptosis is a process of programmed cell death and plays a central role in the development of multicellular organisms. It is a highly regulated process and induces cell death by activating caspases, which are the members of cysteine aspartic acid-specific protease (caspase) family. Caspases involved in apoptosis are classified by their mechanism of action as initiator caspases (caspase-2, -8, -9 and -10) and executioner caspases (caspase-3, -6, and -7). Inhibition of apoptosis results in number of cancers, autoimmune diseases, inflammatory diseases and viral infection. ", "TOX21_CAR_Antagonist assay  was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human constitutive androstane receptor (CAR)  [GeneSymbol:NR1I3] stimulated with CITCO", "TOX21_RT_HEPG2_GLO_32hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "TOX21_p53_BLA_p1_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "Changes to bioluminescence signals produced from the luciferase induction are indicative of agonist activity regulated by the receptor function and kinetics for the human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element MRE, which is responsive to the endogenous human metal-regulatory transcription factor 1 [GeneSymbol:MTF1 | GeneID:4520 | Uniprot_SwissProt_Accession:Q14872].", "TOX21_p53_BLA_p5_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "TOX21_p53_BLA_p3_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C", "TOX21_RT_HEK293_FLO_16hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_RT_HEK293_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element LXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 2 and nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H2 & NR1H3 | GeneID:7376 & 10062 | Uniprot_SwissProt_Accession:P55055 & Q13133].", "TOX21_RT_HEPG2_GLO_40hr_viability was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [Profurimazine]. Changes are indicative of changes in the number of viable cells which are required for reduction of Profurimazine to a form that can be used by NanoLuc luciferase added as a detection reagent. ", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element AhRE, which is responsive to the endogenous human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-1, which is responsive to the endogenous human FBJ murine osteosarcoma viral oncogene homolog and jun proto-oncogene [GeneSymbol:FOS & JUN | GeneID:2353 & 3725 | Uniprot_SwissProt_Accession:P01100 & P05412].", "Metabolically-competent HepaRG cell cultures were exposed to a chemical for 48 hours before cytotoxicty (LDH) and alterations in transcription were assessed.", "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and growth factors.", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PPRE, which is responsive to the endogenous human peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor delta and peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARA & PPARD & PPARG | GeneID:5465 & 5467 & 5468 | Uniprot_SwissProt_Accession:Q07869 & Q03181 & P37231].", "Proliferation in the 3C system is a measure of endothelial cell profliferation which is important to the process of wound healing and angiogensis.", "TOX21_PPARD_BLA_Antagonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886", "TOX21_AR_BLA_Agonist_ratio was designed to  target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881 ", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HIF1a, which is responsive to the endogenous human hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) [GeneSymbol:HIF1A | GeneID:3091 | Uniprot_SwissProt_Accession:Q16665].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Oct, which is responsive to the endogenous human POU class 2 homeobox 1 [GeneSymbol:POU2F1 | GeneID:5451 | Uniprot_SwissProt_Accession:P14859].", "TOX21_HSE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG", "TOX21_RT_HepG2_FLO_08hr_viability was designed to measure changes to biofluorescent signals produced from the key cyanine dye [CellTox Green] binding to dead cell DNA. Increases are indicative of decreased  viable cells present in the culture", "TOX21_H2AX_HTRF_CHO_Agonist_ratio  was designed to target protein phosphorylation, specifically mapping to H2AFX gene(s) using a positive control of Etoposide", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SREBP, which is responsive to the endogenous human sterol regulatory element binding transcription factor 1 [GeneSymbol:SREBF1 | GeneID:6720 | Uniprot_SwissProt_Accession:P36956].", "TOX21_HDAC_Inhibition was designed to target enzymatic activity specifically mapping to HDAC1 gene(s) using a positive control of Trichostatin A", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRb, also known as human retinoid X receptor, beta [GeneSymbol:RXRB | GeneID:6257 | Uniprot_SwissProt_Accession:P28702].", "HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903].", "TOX21_VDR_BLA_Antagonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene EGR, which is responsive to the endogenous human early growth response 1 [GeneSymbol:EGR1 | GeneID:1958 | Uniprot_SwissProt_Accession:P18146].", "TOX21_GR_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Xbp1, which is responsive to the endogenous human X-box binding protein 1 [GeneSymbol:XBP1 | GeneID:7494 | Uniprot_SwissProt_Accession:P17861].", "TOX21_ERa_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ISRE, which is responsive to the endogenous human interferon regulatory factor 1 [GeneSymbol:IRF1 | GeneID:3659 | Uniprot_SwissProt_Accession:P10914].", "SRB in the 3C system is a measure of the total protein content of venular endothelial cells.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Pax, which is responsive to the endogenous human paired box 6 [GeneSymbol:PAX6 | GeneID:5080 | Uniprot_SwissProt_Accession:P26367].", "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", "CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942].", "Eotaxin-3 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 26 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL26 | GeneID:10344 | Uniprot_SwissProt_Accession:Q9Y258].", "Collagen antibody is used to tag and quantify the level of collagen, type III, alpha 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:COL3A1 | GeneID:1281 | Uniprot_SwissProt_Accession:P02461].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element BRE, which is responsive to the endogenous human SMAD family member 1 [GeneSymbol:SMAD1 | GeneID:4086 | Uniprot_SwissProt_Accession:Q15797].", "Proliferation in the CASM3C system is a measure of coronary artery smooth muscle cell proliferation which is important to the process of vasacular biology and restenosis.", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TCF/b-cat, which is responsive to the endogenous human transcription factor 7 (T-cell specific, HMG-box) and transcription factor 7-like 2 (T-cell specific, HMG-box) and lymphoid enhancer-binding factor 1 and transcription factor 7-like 1 (T-cell specific, HMG-box) [GeneSymbol:TCF7 & TCF7L2 & LEF1 & TCF7L1 | GeneID:6932 & 6934 & 51176 & 83439 | Uniprot_SwissProt_Accession:P36402 & Q9NQB0 & Q9UJU2 & Q9HCS4].", "TOX21_TSHR_HTRF_Agonist_ratio was designed to target  receptor activation through increased cAMP generation, specifically mapping to TSHR gene(s) using a positive control of TSH.", "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", "CD38 antibody is used to tag and quantify the level of CD38 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD38 | GeneID:952 | Uniprot_SwissProt_Accession:P28907].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RORE, which is responsive to the endogenous human RAR-related orphan receptor A and RAR-related orphan receptor B and RAR-related orphan receptor C [GeneSymbol:RORA & RORB & RORC | GeneID:6095 & 6096 & 6097 | Uniprot_SwissProt_Accession:P35398 & Q92753 & P51449].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene PBREM, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", "CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942].", "CD69 antibody is used to tag and quantify the level of CD69 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD69 | GeneID:969 | Uniprot_SwissProt_Accession:Q07108].", "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HSE, which is responsive to the endogenous human heat shock transcription factor 1 [GeneSymbol:HSF1 | GeneID:3297 | Uniprot_SwissProt_Accession:Q00613].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RARE, which is responsive to the endogenous human retinoic acid receptor, alpha and retinoic acid receptor, beta and retinoic acid receptor, gamma [GeneSymbol:RARA & RARB & RARG | GeneID:5914 & 5915 & 5916 | Uniprot_SwissProt_Accession:P10276 & P10826 & P13631].", "P-Selectin antibody is used to tag and quantify the level of selectin P (granule membrane protein 140kDa, antigen CD62) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:SELP | GeneID:6403 | Uniprot_SwissProt_Accession:P16109].", "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", "PGE2 antibody is used to tag and quantify the level of prostaglandin E receptor 2 (subtype EP2), 53kDa protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:PTGER2 | GeneID:5732 | Uniprot_SwissProt_Accession:P43116].", "PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121].", "MMP-9 antibody is used to tag and quantify the level of matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:MMP9 | GeneID:4318 | Uniprot_SwissProt_Accession:P14780].", "TNF-a antibody is used to tag and quantify the level of tumor necrosis factor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:TNF | GeneID:7124 | Uniprot_SwissProt_Accession:P01375].", "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element CRE, which is responsive to the endogenous human cAMP responsive element binding protein 3 [GeneSymbol:CREB3 | GeneID:10488 | Uniprot_SwissProt_Accession:O43889].", "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene p53, which is responsive to the endogenous human tumor protein p53 [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human androgen receptor and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:AR & SRC | GeneID:367 & 6714 | Uniprot_SwissProt_Accession:P10275 & P12931].", "Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Alamar blue] are correlated to the viability of the cells in the system.", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "TOX21_RXR_BLA_Agonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to RXRA gene(s) using a positive control of 9-cis-Retinoic acid", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene IR1, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", "MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", "Loss of DHT-induced red fluorescence in nucleolar region of the cell nucleus is consistent with antagonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NF-kB, which is responsive to the endogenous human nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [GeneSymbol:NFKB1 | GeneID:4790 | Uniprot_SwissProt_Accession:P19838].", "TOX21_HRE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HIF1A gene(s) using a positive control of Cobalt(II)chloride hexahydrate", "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", "Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Sp1, which is responsive to the endogenous human Sp1 transcription factor [GeneSymbol:SP1 | GeneID:6667 | Uniprot_SwissProt_Accession:P08047].", "SRB in the 4H system is a measure of the total protein content of venular endothelial cells.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ebox, which is responsive to the endogenous human upstream transcription factor 1 [GeneSymbol:USF1 | GeneID:7391 | Uniprot_SwissProt_Accession:P22415].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "Hoechst-33342 dye is used as a stain for DNA to understand viability in the system.", "uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405].", "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator.", "IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778].", "MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956].", "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation.", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase and nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:SRC & NR1H4 | GeneID:6714 & 9971 | Uniprot_SwissProt_Accession:P12931 & Q96RI1].", "VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320].", "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", "TIMP-2 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TIMP2 | GeneID:7077 | Uniprot_SwissProt_Accession:Q96MC4].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121].", "IL-a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", "E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581].", "IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", "Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204].", "Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor which binds the tripeptide thyrotropin releasing hormone. TRHR is found in the brain and, when bound by TRH, acts (through phospholipase C) to increase intracellular inositol trisphosphate. It plays a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid stimulating hormone and prolactin. Inactivation of this GPCR is indicated by decreased intracellular calcium as measured in this cell-based fluorescent assay.", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 and estrogen receptor 2 (ER beta) [GeneSymbol:ESR1 & ESR2 | GeneID:2099 & 2100 | Uniprot_SwissProt_Accession:P03372 & Q92731].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene C/EBP, which is responsive to the endogenous human CCAAT/enhancer binding protein (C/EBP), beta [GeneSymbol:CEBPB | GeneID:1051 | Uniprot_SwissProt_Accession:P17676].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NFI, which is responsive to the endogenous human nuclear factor I/A [GeneSymbol:NFIA | GeneID:4774 | Uniprot_SwissProt_Accession:Q12857].", "TOX21_PGC_ERR_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human estrogen-related receptor alpha  [GeneSymbol:ESRRA | GeneID:2101| in the presence of PGC1a expression", "IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583].", "TOX21_TSHR_HTRF_Antagonist_ratio was designed to target  receptor inhibition through decreased cAMP generation, specifically mapping to TSHR gene(s) using a positive control of no TSH stimulation", "TIMP-1 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:TIMP1 | GeneID:7076 | Uniprot_SwissProt_Accession:P01033].", "CD142 Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726].", "tPA antibody is used to tag and quantify the level of plasminogen activator, tissue protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAT | GeneID:5327 | Uniprot_SwissProt_Accession:P00750].", "TOX21_ESRE_BLA_ratio was designed to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG", "M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603].", "MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARa, also known as human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869].", "uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749].", "uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749].", "TOX21_RAR_LUC_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human retinoic acid receptor alpha  [GeneSymbol:RARA]", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 2 (ER beta) [GeneSymbol:ESR2 | GeneID:2100 | Uniprot_SwissProt_Accession:Q92731].", "TOX21_PPARg_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SOX, which is responsive to the endogenous human SRY (sex determining region Y)-box 1 [GeneSymbol:SOX1 | GeneID:6656 | Uniprot_SwissProt_Accession:O00570].", "IL-6 antibody is used to tag and quantify the level of interleukin 6 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL6 | GeneID:3569 | Uniprot_SwissProt_Accession:P05231].", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] in the presence of an AR agonist. Changes are indicative of  transcriptional gene expression that may not be due to direct regulation by the human androgen receptor [GeneSymbol: NR3C4 | GeneID: NR3C4 | Uniprot_SwissProt_Accession:].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human nuclear receptor subfamily 4, group A, member 2 and retinoid X receptor, alpha [GeneSymbol:NR4A2 & RXRA | GeneID:4929 & 6256 | Uniprot_SwissProt_Accession:P43354 & P19793].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-2, which is responsive to the endogenous human transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) and transcription factor AP-2 beta (activating enhancer binding protein 2 beta) and transcription factor AP-2 delta (activating enhancer binding protein 2 delta) [GeneSymbol:TFAP2A & TFAP2B & TFAP2D | GeneID:7020 & 7021 & 83741 | Uniprot_SwissProt_Accession:P05549 & Q92481 & Q7Z6R9].", "LDLR antibody is used to tag and quantify the level of low density lipoprotein receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:LDLR | GeneID:3949 | Uniprot_SwissProt_Accession:P01130].", "TGF-b1 antibody is used to tag and quantify the level of transforming growth factor, beta 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", "ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TGF, which is responsive to the endogenous human transforming growth factor, beta 1 [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", "TOX21_PPARD_BLA_Agonist_ratio was designed to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041", "SRB in the CASM3C system is a measure of the total protein content of coronary artery smooth muscle cells.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NRF1, which is responsive to the endogenous human nuclear respiratory factor 1 [GeneSymbol:NRF1 | GeneID:4899 | Uniprot_SwissProt_Accession:Q16656].", "Serum Amyloid A (SAA) is a member of the apolipoprotein family that is an acute phase reactant.  SAA is categorized as an inflammation-related activity in the CASM3C system modeling Th1 vascular smooth muscle inflammation. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SAA1 | GeneID:6288 | Uniprot_SwissProt_Accession:P0DJI8].", "0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and TGFb.", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myc, which is responsive to the endogenous human v-myc avian myelocytomatosis viral oncogene homolog [GeneSymbol:MYC | GeneID:4609 | Uniprot_SwissProt_Accession:P01106].", "anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243].", "VEGFRII antibody is used to tag and quantify the level of kinase insert domain receptor (a type III receptor tyrosine kinase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:KDR | GeneID:3791 | Uniprot_SwissProt_Accession:P35968].", "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", "Changes to optical microscopy: fluorescence microscopy signals produced from the fluorescent protein induction are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "SRB in the BE3C system is a measure of the total protein content of bronchial epithelial cells.  Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells.", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ets, which is responsive to the endogenous human v-ets avian erythroblastosis virus E26 oncogene homolog 1 [GeneSymbol:ETS1 | GeneID:2113 | Uniprot_SwissProt_Accession:P14921].", "Decrease of the ratio of DHT-induced red fluorescence in nucleolar region of the cell nucleus to the red fluorescence localized in the cytoplasm is consistent with antagonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-NURR1, also known as human nuclear receptor subfamily 4, group A, member 2 [GeneSymbol:NR4A2 | GeneID:4929 | Uniprot_SwissProt_Accession:P43354].", "ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362].", "IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145].", "Anti-phospho-histone-H2AX antibody is used to tag and quantify the level of phosphorylated H2A histone family, member X protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H2AFX | GeneID:3014 | Uniprot_SwissProt_Accession:P16104].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GLI, which is responsive to the endogenous human GLI family zinc finger 1 [GeneSymbol:GLI1 | GeneID:2735 | Uniprot_SwissProt_Accession:P08151].", "Thyrotropin-releasing hormone (TRH) receptor (TRHR) is a G-protein-coupled receptor which binds the tripeptide thyrotropin releasing hormone. TRHR is found in the brain and, when bound by TRH, acts (through phospholipase C) to increase intracellular inositol trisphosphate. It plays a crucial role in the anterior pituitary where it controls the synthesis and secretion of thyroid stimulating hormone and prolactin. Intracellular calcium is measured as an indicator of Gq-coupled human thyrotropin-releasing hormone receptor (TRHR) activation using fluorescent detection in a TRHR-Hek293 cell-based assay. Activation of this GPCR is indicated by increased intracellular calcium as measured in this cell-based fluorescent reporter assay.", "MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325].", "Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system.", "EGFR antibody is used to tag and quantify the level of epidermal growth factor receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:EGFR | GeneID:1956 | Uniprot_SwissProt_Accession:P00533].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxO, which is responsive to the endogenous human forkhead box O1 and forkhead box O3 [GeneSymbol:FOXO1 & FOXO3 | GeneID:2308 & 2309 | Uniprot_SwissProt_Accession:Q12778 & O43524].", "TGF-b1 antibody is used to tag and quantify the level of transforming growth factor, beta 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HNF6, which is responsive to the endogenous human one cut homeobox 1 [GeneSymbol:ONECUT1 | GeneID:3175 | Uniprot_SwissProt_Accession:Q9UBC0].", "TOX21_FXR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid", "anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637].", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] in the presence of an ER antagonist. Changes are indicative of  transcriptional gene expression that may not be due to direct regulation by the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element GRE, which is responsive to the endogenous human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", "Increased red fluorescence in nucleolar region of the cell nucleus is consistent with agonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", "TOX21_ERb_BLA_Agonist_ch2 was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR2 gene(s) using a positive control of 17b-estradiol", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene E2F, which is responsive to the endogenous human E2F transcription factor 1 [GeneSymbol:E2F1 | GeneID:1869 | Uniprot_SwissProt_Accession:Q01094].", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [D-luciferin] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "MitoTracker Red is used as a stain for the membrane potential of the mitochondria.", "Increased ratio of DHT-induced red fluorescence in nucleolar region of the cell nucleus to the red fluorescence localized in the cytoplasm is consistent with agonism of human androgen receptor activity [GeneSymbol: AR | GeneID: 367 |", "TOX21_NFkB_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myb, which is responsive to the endogenous human v-myb avian myeloblastosis viral oncogene homolog [GeneSymbol:MYB | GeneID:4602 | Uniprot_SwissProt_Accession:P10242].", "MitoTracker Red is used as a stain for the morphology of the mitochondria.", "anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36].", "Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human ATPase family, AAA domain containing 5 [GeneSymbol:ATAD5 | GeneID:79915 | Uniprot_SwissProt_Accession:Q96QE3].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxA, which is responsive to the endogenous human forkhead box A2 [GeneSymbol:FOXA2 | GeneID:3170 | Uniprot_SwissProt_Accession:Q9Y261].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GATA, which is responsive to the endogenous human GATA binding protein 1 (globin transcription factor 1) [GeneSymbol:GATA1 | GeneID:2623 | Uniprot_SwissProt_Accession:P15976].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene STAT, which is responsive to the endogenous human signal transducer and activator of transcription 3 (acute-phase response factor) [GeneSymbol:STAT3 | GeneID:6774 | Uniprot_SwissProt_Accession:P40763].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-FXR, also known as human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-THRa, also known as human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRa, also known as human retinoid X receptor, alpha [GeneSymbol:RXRA | GeneID:6256 | Uniprot_SwissProt_Accession:P19793].", "anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412].", "TOX21_VDR_BLA_Agonist_ratio was designed to measure cleaved reporter gene substrate to target nuclear receptor  activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARd, also known as human peroxisome proliferator-activated receptor delta [GeneSymbol:PPARD | GeneID:5467 | Uniprot_SwissProt_Accession:Q03181].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRa, also known as human nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H3 | GeneID:10062 | Uniprot_SwissProt_Accession:Q13133].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-GR, also known as human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARa, also known as human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRb, also known as human nuclear receptor subfamily 1, group H, member 2 [GeneSymbol:NR1H2 | GeneID:7376 | Uniprot_SwissProt_Accession:P55055].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARg, also known as human retinoic acid receptor, gamma [GeneSymbol:RARG | GeneID:5916 | Uniprot_SwissProt_Accession:P13631].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-VDR, also known as human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-AR, also known as human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275].", "TOX21_TSHR_wt_HTRF_ratio was designed to target  background cAMP generation in cells lacking TSHR", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-HNF4a, also known as human hepatocyte nuclear factor 4, alpha [GeneSymbol:HNF4A | GeneID:3172 | Uniprot_SwissProt_Accession:P41235].", "TOX21_SHH_3T3_GLI3_Agonist was designed to measure changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo]. Changes are indicative of changes in transcriptional gene expression due to agonist activity regulated by Gli3, part of the sonic hedgehog (Shh) pathway", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-CAR, also known as human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994].", "Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:PPARG & SRC | GeneID:5468 & 6714 | Uniprot_SwissProt_Accession:P37231 & P12931].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARb, also known as human retinoic acid receptor, beta [GeneSymbol:RARB | GeneID:5915 | Uniprot_SwissProt_Accession:P10826].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORg, also known as human RAR-related orphan receptor C [GeneSymbol:RORC | GeneID:6097 | Uniprot_SwissProt_Accession:P51449].", "Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRg, also known as human estrogen-related receptor gamma [GeneSymbol:ESRRG | GeneID:2104 | Uniprot_SwissProt_Accession:P62508]."], "parameter_readout_type": ["single", "multiple"], "assay_design_type": ["inducible reporter", "viability reporter", "membrane potential reporter", "growth reporter", "binding reporter", "biochemical reporter", "morphology reporter", "background reporter", "conformation reporter", "enzyme reporter"], "assay_design_type_sub": ["luciferase induction", "beta lactamase induction", "mRNA induction", "ATP content", "dye binding", "living cells", "dead cells", "real-time cell-growth kinetics", "metabolic activity", "protein content", "immunoassay: elisa", "cAMP measurement", "protein fragment complementation assay", "dehydrogenase activity determination", "protein-protein binding", "cell number", "caspase activity", "intracellular calcium", "cell phenotype", "fluorescent protein induction", "dna content", "artifact detection", "protein conformation", "enzyme activity"], "biological_process_target": ["regulation of transcription factor activity", "cell proliferation", "mitochondrial depolarization", "cytotoxicity", "regulation of gene expression", "cell death", "protein stabilization", "receptor binding", "apoptosis", "receptor activation", "cell cycle", "oxidative phosphorylation", "artifact detection"], "detection_technology_type": ["Luminescence", "Fluorescence", "Label Free Technology", "Spectrophotometry", "Microscopy"], "detection_technology_type_sub": ["Bioluminescence", "Fluorescence intensity", "Electrical Sensor: Impedance", "Absorbance", "Optical microscopy: Fluorescence microscopy"], "detection_technology": ["CellTiter-Glo Luciferase-coupled ATP quantitation", "GAL4 b-lactamase reporter gene", "RT-PCR and Capillary electrophoresis", "RealTime-Glo MT Cell Viability Assay", "homogenous mitochondrial membrane potential assay", "Cell Titer Fluor assay ", "Cell Titer Fluor assay", "Fluorescence emission", "RT-CES", "CALUX luciferase quantitation", "Fluidigm qRT-PCR", "Sulforhodamine staining", "Homogeneous Time Resolved Fluorescence", "ELISA", "Protein-fragment Complementation", "Alamar Blue Reduction", "HCS Fluorescent Imaging", "Caspase-Glo 3/7", "FDSS 7000EX kinetic plate reader\u00a0", "Microscopy", "Enzyme activity", "Luciferase"], "key_assay_reagent_type": ["substrate", "inducer", "stain", "NA", null, "antibody", "chemical"], "key_assay_reagent": ["One-Glo", "CCF4-AM", "PXRE RTU", "NanoLuc/profurimazine", "Mito-MPS", "CellTiter-Fluor reagent", "CellTiter-Glo", "CellTox Green", "ARE RTU", "GAL4-PXR RTU", "GAL4-PPARg RTU", "VDRE RTU", "NA", "ERE RTU", "GAL4-ERa RTU", "MRE RTU", "LXRE RTU", "AhRE RTU", "AP-1 RTU", null, "0.1% sulforhodamine", "PPRE RTU", "HIF1a RTU", "Oct RTU", "SREBP RTU", "GAL4-RXRb RTU", "HLA-DR antibody", "EGR RTU", "Xbp1 RTU", "ISRE RTU", "IP-10 antibody", "Pax RTU", "E-selectin antibody", "CD40 antibody", "Eotaxin-3 antibody", "Collagen antibody", "BRE RTU", "TCF/b-cat RTU", "d2-labeled cAMP", "VCAM-1 antibody", "CD38 antibody", "RORE RTU", "PBREM RTU", "M-CSF antibody", "CD69 antibody", "HSE RTU", "RARE RTU", "P-Selectin antibody", "uPAR antibody", "PGE2 antibody", "PAI-1 antibody", "MMP-9 antibody", "TNF-a antibody", "IL-8 antibody", "CRE RTU", "p53 RTU", "Alamar blue", "MCP-1 antibody", "IR1 RTU", "MMP-1 antibody", "NF-kB RTU", "Tissue Factor antibody", "Sp1 RTU", "Ebox RTU", "Hoechst-33342 dye", "MIG antibody", "Caspase-Glo 3/7 reagent", "TIMP-2 antibody", "IL-a antibody", "IL-1a antibody", "Thrombomodulin antibody", "intracellular calcium", "C/EBP RTU", "NFI RTU", "TIMP-1 antibody", "CD142 Tissue Factor antibody", "tPA antibody", "GAL4-PPARa RTU", "uPA antibody", "SOX RTU", "IL-6 antibody", "AP-2 RTU", "LDLR antibody", "TGF-b1 antibody", "ICAM-1 antibody", "TGF RTU", "NRF1 RTU", "SAA antibody", "Myc RTU", "anti-phospho-histone-H3 antibody", "VEGFRII antibody", "Ets RTU", "GAL4-NURR1 RTU", "anti-phospho-histone-H2AX antibody", "GLI RTU", "EGFR antibody", "FoxO RTU", "HNF6 RTU", "anti-p53 antibody", "GRE RTU", "E2F RTU", "D-luciferin", "MitoTracker Red", "Myb RTU", "anti-a-tubulin antibody", "FoxA RTU", "GATA RTU", "STAT RTU", "GAL4-FXR RTU", "GAL4-THRa RTU", "GAL4-RXRa RTU", "anti-phospho-c-jun antibody", "GAL4-PPARd RTU", "GAL4-LXRa RTU", "GAL4-GR RTU", "GAL4-RARa RTU", "GAL4-LXRb RTU", "GAL4-RARg RTU", "GAL4-VDR RTU", "GAL4-AR RTU", "GAL4-HNF4a RTU", "GAL4-CAR RTU", "GAL4-RARb RTU", "GAL4-RORg RTU", "GAL4-ERRg RTU"], "technological_target_type": ["protein", "rna", "chemical", "cellular", "cell morphology", "dna", "chemical "], "technological_target_type_sub": ["receptor", "mRNA", "protein-unspecified", "enzyme", "mitochondria", "cellular", "ATP", "dna-unspecified", "protein-specified", "receptor binding", "intracellular calcium"], "asid": [7, 3, 1, 9, 4, 6, 25, 2], "assay_name": ["TOX21_PXR", "TOX21_TR_LUC_GH3_Antagonist", "TOX21_PR_BLA_Antagonist", "ATG_CIS", "TOX21_RT_HEK293", "TOX21_ERR", "TOX21_SHH_3T3_GLI3_Antagonist", "TOX21_AR_BLA_Antagonist", "TOX21_MMP", "TOX21_ARE_BLA_Agonist", "TOX21_CASP3_CHO", "TOX21_ERb_BLA_Antagonist", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_RT_HEPG2", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_ERb_BLA_Agonist", "TOX21_ERa_BLA_Antagonist", "TOX21_PGC_ERR", "TOX21_Aromatase_Inhibition", "TOX21_SHH_3T3_GLI3_Agonist", "TOX21_SBE_BLA_Antagonist", "TOX21_FXR_BLA_Antagonist", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "ATG_TRANS", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_CAR_Antagonist", "TOX21_HRE_BLA_Agonist", "TOX21_AP1_BLA_Agonist", "TOX21_RXR_BLA_Agonist", "TOX21_CAR_Agonist", "TOX21_VDR_BLA_Agonist", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RAR_LUC_Antagonist", "ACEA_ER", "TOX21_PPARd_BLA_Agonist", "TOX21_GR_BLA_Antagonist", "TOX21_PR_BLA_Agonist", "TOX21_p53_BLA_p2", "TOX21_H2AX_HTRF_CHO_Agonist", "TOX21_PPARg_BLA_Antagonist", "TOX21_AhR_LUC_Agonist", "TOX21_p53_BLA_p4", "TOX21_CASP3_HEPG2", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide", "TOX21_p53_BLA_p1", "TOX21_p53_BLA_p5", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "TOX21_p53_BLA_p3", "LTEA_HepaRG", "BSK_hDFCGF", "ACEA_AR_antagonist", "BSK_3C", "TOX21_PPARd_BLA_Antagonist", "TOX21_AR_BLA_Agonist", "TOX21_NFkB_BLA_Agonist", "TOX21_HSE_BLA_Agonist", "TOX21_HDAC_Inhibition", "TOX21_ELG1_LUC_Agonist", "TOX21_VDR_BLA_Antagonist", "TOX21_GR_BLA_Agonist", "ACEA_AR_agonist", "TOX21_ERa_BLA_Agonist", "TOX21_RAR_LUC_Agonist", "BSK_SAg", "TOX21_FXR_BLA_Agonist", "TOX21_ESRE_BLA", "BSK_4H", "BSK_CASM3C", "TOX21_TSHR_Agonist", "BSK_LPS", "BSK_BE3C", "BSK_KF3CT", "TOX21_AR_LUC_MDAKB2_Agonist", "OT_AR_ARSRC1_0960", "UPITT_AR_TIF2_PPIB", "APR_HepG2_72hr", "OT_FXR_FXRSRC1_0480", "TOX21_SBE_BLA_Agonist", "TOX21_TRHR_HEK293", "OT_ER_ERaERb_1440", "OT_AR_ARSRC1_0480", "TOX21_TSHR_Antagonist", "OT_FXR_FXRSRC1_1440", "OT_ER_ERaERb_0480", "OT_ER_ERbERb_1440", "TOX21_PPARg_BLA_Agonist", "OT_ER_ERbERb_0480", "APR_HepG2_24hr", "OT_NURR1_NURR1RXRa_0480", "OT_ERa_GFPERaERE_0120", "OT_ERa_GFPERaERE_0480", "OT_NURR1_NURR1RXRa_1440", "OT_ER_ERaERa_1440", "OT_ER_ERaERa_0480", "OT_AR_ARELUC_AG_1440", "TOX21_TSHR_wt", "OT_PPARg_PPARgSRC1_1440", "OT_PPARg_PPARgSRC1_0480"], "assay_desc": ["The TOX21_PXR is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing on a microplate: 1536-well plate. To screen Tox21 libraries for compounds that activate hPXR-mediated CYP3A4 gene expression, PXR-Luc HepG2 cells were used. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", "TOX21_TR_LUC_GH3_Antagonist is a cell-based, single-readout assay that uses GH3, a rat pituitary gland cell line, with measurements taken at 28 hours after chemical dosing in a 1536-well plate.", "TOX21_PR_BLA_Antagonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells. ", "ATG_CIS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", "TOX21_RT_HEK293 is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ERR is a cell-based, single-readout assay that uses ERR-HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_SHH_3T3_GLI3_Antagonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", "TOX21_AR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_MMP (Mitochondrial Membrane Potential) is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ARE_BLA_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "The TOX21_CASP3_CHO is a cell-based, single-readout assay that uses CHO-K1, a hamster ovary cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate.  To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. Wild type CHO-K1 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", "TOX21_ERb_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. ", "TOX21_RT_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ERa_LUC_VM7_Agonist is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate.", "TOX21_ERb_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ERa_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_PGC_ERR is a cell-based, single-readout assay that uses PGC/ERR HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_Aromatase_Inhibition is a cell-based, single-readout assay that uses MCF-7, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_SHH_3T3_GLI3_Agonist is a cell-based, single-readout assay that uses NIH/3T3, a mouse embryo cell line, with measurements taken at 24 hours after chemical dosing in a 1536 well.", "The TOX21_SBE_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", "TOX21_FXR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 48 hours after chemical dosing in a 1536-well plate.", "ATG_TRANS is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 24-well plate.", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for antagonist specificity. ", "TOX21_CAR_Antagonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_HRE_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_AP1_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_RXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_CAR_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_VDR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2.", "TOX21_RORg_LUC_CHO_Antagonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 17 hours after chemical dosing in a 1536-well plate.", "TOX21_RAR_LUC_Antagonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", "ACEA_ER is a cell-based, single-readout assay that uses T47D, a human breast cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", "TOX21_PPARd_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_GR_BLA_Antagonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_PR_BLA_Agonist is a cell-based, single-readout assay that uses transfected HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. To identify the compounds that stimulate PR signaling, a PR-UAS-bla GripTite cell line i.e. PR-UAS-bla HEK293T (Invitrogen, Carlsbad, CA, USA) containing a beta-lactamase reporter gene under the control of an UAS response element was used to screen Tox21 10K compound library. The cytotoxicity of the Tox21 compound library against the PR-bla cell line was tested in parallel by measuring the cell viability using CellTiter-Glo assay in the same wells.", "TOX21_p53_BLA_p2 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_H2AX_HTRF_CHO_Agonist is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_PPARg_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_AhR_LUC_Agonist is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_p53_BLA_p4 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "The TOX21_CASP3_HEPG2 is a cell-based, single-readout assay that uses HepG2, a human liver cell line, with measurements taken at 16 hours after chemical dosing on a microplate: 1536-well plate. To identify small molecule compounds that induce apoptosis, a homogeneous, luminescent Caspase-Glo 3/7 assay was used. HepG2 cells were used to screen Tox21 libraries for identifying caspase-3/7 activity inducers. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Fluor assay system in the same wells.", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. This is an secondary assay to TOX21_AR_LUC_MDAKB2_Agonist for agonist specificity. This particular screening for measuring luciferase reporter gene activity using MDA-kb2 cells against Tox21 10K library compounds is a confirmation study on agonist mode screening in the presence of AR-antagonist compound (Nilutamide) at 3.0uM final concentration. ", "TOX21_p53_BLA_p1 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_p53_BLA_p5 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780 is a cell-based, single-readout assay that uses VM7, a human breast tissue cell line, with measurements taken at 22 hours after chemical dosing in a 1536-well plate. This is a secondary assay for specificity to TOX21_ERa_LUC_VM7_Agonist.", "TOX21_p53_BLA_p3 is a cell-based, single-readout assay that uses HCT116, a human intestinal cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "LTEA_HepaRG is a cell based, multiplexed-readout assay that uses HepaRG, a human liver cell line, with measurements taken at 48 hours after chemical dosing on a 96-well plate.", "BSK_hDFCGF is a cell-based, multiplexed-readout assay that uses foreskin fibroblast, a human skin primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", "ACEA_AR_antagonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", "BSK_3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", "TOX21_PPARd_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_AR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_NFkB_BLA_Agonist is a cell-based, single-readout assay that uses ME-180, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_HSE_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_HDAC_Inhibition is a cell-based, single-readout assay that uses HCT-116, a human colon cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ELG1_LUC_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_VDR_BLA_Antagonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_GR_BLA_Agonist is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "ACEA_AR_agonist is a cell-based, single-readout assay that uses 22Rv1, a human prostate cancer cell line, with measurements taken at 80 hours after chemical dosing in a 96-well or 384-well plate.", "TOX21_ERa_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_RAR_LUC_Agonist is a cell-based, single-readout assay that uses C3H10T1/2, a mouse sarcoma cell line, with measurements taken at 6 hours after chemical dosing in a 1536-well plate.", "BSK_SAg is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", "TOX21_FXR_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "TOX21_ESRE_BLA is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "BSK_4H is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium, a human vascular primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", "BSK_CASM3C is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and coronary artery smooth muscle cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", "Tox21_TSHR_Agonist  is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", "BSK_LPS is a cell-based, multiplexed-readout assay that uses umbilical vein endothelium and peripheral blood mononuclear cells, a human vascular primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", "BSK_BE3C is a cell-based, multiplexed-readout assay that uses bronchial epithelial cell, a human lung primary cell, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", "BSK_KF3CT is a cell-based, multiplexed-readout assay that uses keratinocytes and foreskin fibroblasts, a human skin primary cell co-culture, with measurements taken at 24 hours after chemical dosing in a 96-well plate.", "TOX21_AR_LUC_MDAKB2_Agonist is a cell-based, single-readout assay that uses MDA-kb2, a human breast cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "OT_AR_ARSRC1_0960 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 16 hours after chemical dosing in a 384-well plate.", "UPITT_AR_TIF2_PPIB is a cell-based, high-content imaging assay that uses U2OS, a human osteosarcoma cell line, expressing a human androgen receptor fused to red fluorescent protein and the coactivator TIF2 fused to green fluorescent protein. ", "APR_HepG2_72hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 72 hours after chemical dosing in a 384-well plate.", "OT_FXR_FXRSRC1_0480  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", "The TOX21_SBE_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T , a human kidney cell line, with measurements taken at 5 hours after chemical dosing on a microplate: 1536-well plate. This cell line contains a beta-lactamase reporter gene under control of the Smad binding element (SBE) stably integrated into HEK 293T cells. Cytotoxicity of the compounds was tested in parallel by measuring the cell viability using CellTiter-Glo assay system in the same wells.", "TOX21_TRHR_HEK293 assay is a cell-based assay, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate. It has the potential to screen G protein-coupled receptors. A compound/drug can either activate (agonist) or suppress (antagonist) GPCRs that can be monitored by levels of intracellular calcium. Using this assay, the Tox21 10K compound library was screened to identify potential TRHR agonists.", "OT_ER_ERaERb_1440  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", "OT_AR_ARSRC1_0480 is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", "Tox21_TSHR_Antagonist  is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", "OT_FXR_FXRSRC1_1440  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", "OT_ER_ERaERb_0480  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", "OT_ER_ERbERb_1440  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", "TOX21_PPARg_BLA_Agonist is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 1536-well plate.", "OT_ER_ERbERb_0480  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", "APR_HepG2_24hr is a cell-based, multiplexed-readout assay that uses HepG2, a human liver cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", "OT_NURR1_NURR1RXRa_0480  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", "OT_ERa_GFPERaERE_0120 is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 2 hours after chemical dosing in a 384-well plate.", "OT_ERa_GFPERaERE_0480 is a cell-based, single-readout assay that uses HeLa, a human cervix cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", "OT_NURR1_NURR1RXRa_1440  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", "OT_ER_ERaERa_1440  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", "OT_ER_ERaERa_0480  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate.", "OT_AR_ARELUC_AG_1440 is a cell-based, single-readout assay that uses CHO-K1, a chinese hamster ovary cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", "Tox21_TSHR_wt  is a cell-based, single-readout assay that uses HEK293T, a human kidney cell line, with measurements taken at 0.5 hours after chemical dosing in a 1536-well plate.", "OT_PPARg_PPARgSRC1_1440  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 24 hours after chemical dosing in a 384-well plate.", "OT_PPARg_PPARgSRC1_0480  is a cell-based assay that uses HEK293T, a human kidney cell line, with measurements taken at 8 hours after chemical dosing in a 384-well plate."], "timepoint_hr": [24.0, 28.0, 16.0, 22.0, 5.0, 17.0, 6.0, 80.0, 48.0, 0.5, 3.0, 72.0, 8.0, 20.0, 2.0], "organism_id": [9606, 10116, 10090, 10029], "organism": ["human", "rat", "mouse", "chinese hamster"], "tissue": ["liver", "pituitary gland", "kidney", "embryo", "ovary", "breast", "cervix", "intestinal", "skin", "prostate", "vascular", "colon", "lung", "bone"], "cell_format": ["cell line", "primary cell", "primary cell co-culture"], "cell_free_component_source": ["NA", ""], "cell_short_name": ["HepG2", "GH3", "PR-UAS-bla-HEK293T", "HEK293", "ERR-HEK293T", "NIH/3T3", "HEK293T", "CHO-K1", "MDA-kb2", "VM7", "PGC/ERR HEK293T", "MCF7", "ME-180", "C3H10T1/2", "T47D", "HeLa", "HCT116", "HepaRG", "foreskin fibroblast", "22Rv1", "umbilical vein endothelium", "umbilical vein endothelium and peripheral blood mononuclear cells", "coronary artery smooth muscle cells", "bronchial epithelial cells", "keratinocytes and foreskin fibroblasts", "U2OS"], "cell_growth_mode": ["adherent", null], "assay_footprint": ["microplate: 1536-well plate", "microplate: 24-well plate", "microplate: 384-well plate", "microplate: 96-well plate"], "assay_format_type": ["cell-based"], "assay_format_type_sub": ["cell-based format", "protein complex format"], "content_readout_type": ["single", "multiplexed", "image-based"], "dilution_solvent": ["DMSO"], "dilution_solvent_percent_max": [null, 0.5, 0.1, 1.0, 0.0, 0.2], "new_AssayEndpointName": [null, "TOX21_TR_LUC_GH3_Antagonist", "TOX21_PR_BLA_Antagonist_ratio", "TOX21_RT_HEK293_GLO_40hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability", "TOX21_ERR_Antagonist", "TOX21_RT_HEK293_GLO_24hr_viability", "TOX21_SHH_3T3_GLI3_Antagonist", "TOX21_AR_BLA_Antagonist_ratio", "TOX21_RT_HEK293_GLO_16hr_viability", "TOX21_CASP3_CHO_viability", "TOX21_ERb_BLA_Antagonist_ratio", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_TR_LUC_GH3_Antagonist_viability", "TOX21_PXR_viability", "TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_SHH_3T3_GLI3_Antagonist_viability", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_ERb_BLA_Agonist_viability", "TOX21_ERa_BLA_Antagonist_ratio", "TOX21_PGC_ERR_Antagonist", "TOX21_RT_HEK293_FLO_40hr_viability", "TOX21_Aromatase_Inhibition", "TOX21_SHH_3T3_GLI3_Agonist_viability", "TOX21_ERb_BLA_Antagonist_viability", "TOX21_ERR_viability", "TOX21_SBE_BLA_Antagonist_ratio", "TOX21_Aromatase_Inhibition_viability", "TOX21_AR_BLA_Antagonist_viability", "TOX21_RT_HEPG2_FLO_24hr_viability", "TOX21_PGC_ERR_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "TOX21_RT_HEK293_FLO_32hr_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_CAR_Antagonist_viability", "TOX21_HRE_BLA_Agonist_viability", "TOX21_AP1_BLA_Agonist_ratio", "TOX21_RXR_BLA_Agonist_viability", "TOX21_VDR_BLA_Agonist_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RAR_LUC_Antagonist", "ACEA_ER_AUC_viability", "TOX21_PPARd_BLA_Agonist_viability", "TOX21_RT_HEK293_FLO_24hr_viability", "TOX21_RORg_LUC_CHO_Antagonist_viability", "TOX21_GR_BLA_Antagonist_ratio", "TOX21_PR_BLA_Antagonist_viability", "TOX21_PR_BLA_Agonist_viability", "TOX21_p53_BLA_p2_ratio", "TOX21_H2AX_HTRF_CHO_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", "TOX21_CAR_Agonist", "TOX21_AhR_LUC_Agonist_viability", "TOX21_p53_BLA_p4_viability", "TOX21_p53_BLA_p4_ratio", "TOX21_CASP3_HEPG2_viability", "TOX21_CAR_Antagonist", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", "TOX21_p53_BLA_p1_ratio", "TOX21_AhR_LUC_Agonist", "TOX21_p53_BLA_p5_ratio", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", "TOX21_p53_BLA_p3_ratio", "TOX21_RT_HEK293_FLO_16hr_viability", "TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", "TOX21_ARE_BLA_agonist_viability", "TOX21_RT_HEPG2_GLO_40hr_viability", "TOX21_MMP_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", "TOX21_p53_BLA_p3_viability", "TOX21_GR_BLA_Antagonist_viability", "ACEA_AR_antagonist_80hr", "TOX21_p53_BLA_p2_viability", "ACEA_AR_antagonist_AUC_viability", "TOX21_AR_BLA_Agonist_ratio", "TOX21_NFkB_BLA_agonist_viability", "TOX21_RT_HEPG2_FLO_08hr_viability", "TOX21_H2AX_HTRF_CHO_Agonist_ratio", "TOX21_AP1_BLA_Agonist_viability", "TOX21_p53_BLA_p1_viability", "TOX21_HDAC_Inhibition", "TOX21_ELG1_LUC_Agonist_viability", "TOX21_GR_BLA_Agonist_ratio", "ACEA_AR_agonist_AUC_viability", "TOX21_ERa_BLA_Agonist_ratio", "ACEA_ER_80hr", "TOX21_RAR_LUC_Agonist_viability", "TOX21_FXR_BLA_agonist_viability", "TOX21_ESRE_BLA_viability", "TOX21_TSHR_HTRF_Agonist_ratio", "TOX21_p53_BLA_p5_viability", "TOX21_HSE_BLA_agonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist", "OT_AR_ARSRC1_0960", "TOX21_RXR_BLA_Agonist_ratio", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", "TOX21_HRE_BLA_Agonist_ratio", "TOX21_ERa_BLA_Antagonist_viability", "OT_FXR_FXRSRC1_0480", "TOX21_SBE_BLA_Agonist_viability", "TOX21_CASP3_HEPG2", "TOX21_RAR_LUC_Antagonist_viability", "TOX21_SBE_BLA_Antagonist_viability", "OT_ER_ERaERb_1440", "TOX21_PGC_ERR_Agonist", "OT_AR_ARSRC1_0480", "TOX21_TSHR_HTRF_Antagonist_ratio", "OT_FXR_FXRSRC1_1440", "TOX21_ESRE_BLA_ratio", "TOX21_ERR_Agonist", "TOX21_RAR_LUC_Agonist", "OT_ER_ERaERb_0480", "OT_ER_ERbERb_1440", "TOX21_PPARg_BLA_Agonist_ratio", "OT_ER_ERbERb_0480", "OT_NURR1_NURR1RXRa_0480", "TOX21_PR_BLA_Agonist_ratio", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", "OT_NURR1_NURR1RXRa_1440", "TOX21_HDAC_Inhibition_viability", "OT_ER_ERaERa_1440", "OT_ER_ERaERa_0480", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", "LTEA_HepaRG_LDH_cytotoxicity", "TOX21_CASP3_CHO", "TOX21_ERb_BLA_Agonist_ratio", "OT_AR_ARELUC_AG_1440", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", "TOX21_NFkB_BLA_agonist_ratio", "TOX21_ELG1_LUC_Agonist", "ACEA_AR_agonist_80hr", "TOX21_SBE_BLA_Agonist_ratio", "TOX21_SHH_3T3_GLI3_Agonist", "OT_PPARg_PPARgSRC1_1440", "OT_PPARg_PPARgSRC1_0480"], "old_AssayEndpointName": [null, "TOX21_TR_LUC_GH3_Antagonist", "TOX21_PR_BLA_Antagonist_ratio", "TOX21_RT_HEK293_GLO_40hr_viability", "TOX21_RT_HEK293_GLO_32hr_viability", "TOX21_ERR_Antagonist", "TOX21_RT_HEK293_GLO_24hr_viability", "TOX21_SSH_3T3_GLI3_Antagonist", "TOX21_AR_BLA_Antagonist_ratio", "TOX21_RT_HEK293_GLO_16hr_viability", "TOX21_CASP3_CHO_viability", "TOX21_ERb_BLA_Antagonist_ratio", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881", "TOX21_TR_LUC_GH3_Antagonist_viability", "TOX21_PXR_viability", "TOX21_RT_HEK293_GLO_08hr_viability", "TOX21_SSH_3T3_GLI3_Antagonist_viability", "TOX21_ERa_LUC_VM7_Agonist", "TOX21_ERb_BLA_Agonist_viability", "TOX21_ERa_BLA_Antagonist_ratio", "TOX21_PGC_ERR_Antagonist", "TOX21_RT_HEK293_FLO_40hr_viability", "TOX21_Aromatase_Inhibition", "TOX21_SSH_3T3_GLI3_Agonist_viability", "TOX21_ERb_BLA_Antagonist_viability", "TOX21_ERR_viability", "TOX21_SBE_BLA_Antagonist_ratio", "TOX21_Aromatase_Inhibition_viability", "TOX21_AR_BLA_Antagonist_viability", "TOX21_RT_HEPG2_FLO_24hr_viability", "TOX21_PGC_ERR_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2", "TOX21_RT_HEK293_FLO_32hr_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881", "TOX21_CAR_Antagonist_viability", "TOX21_HRE_BLA_Agonist_viability", "TOX21_AP1_BLA_Agonist_ratio", "TOX21_RXR_BLA_Agonist_viability", "TOX21_VDR_BLA_Agonist_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2", "TOX21_RORg_LUC_CHO_Antagonist", "TOX21_RAR_LUC_Antagonist", "ACEA_ER_AUC_viability", "TOX21_PPARd_BLA_Agonist_viability", "TOX21_RT_HEK293_FLO_24hr_viability", "TOX21_RORg_LUC_CHO_Antagonist_viability", "TOX21_GR_BLA_Antagonist_ratio", "TOX21_PR_BLA_Antagonist_viability", "TOX21_PR_BLA_Agonist_viability", "TOX21_p53_BLA_p2_ratio", "TOX21_H2AX_HTRF_CHO_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability", "TOX21_CAR_Agonist", "TOX21_AhR_LUC_Agonist_viability", "TOX21_p53_BLA_p4_viability", "TOX21_p53_BLA_p4_ratio", "TOX21_CASP3_HEPG2_viability", "TOX21_CAR_Antagonist", "TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability", "TOX21_p53_BLA_p1_ratio", "TOX21_AhR_LUC_Agonist", "TOX21_p53_BLA_p5_ratio", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability", "TOX21_p53_BLA_p3_ratio", "TOX21_RT_HEK293_FLO_16hr_viability", "TOX21_RT_HEK293_FLO_08hr_viability", "TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2_viability", "TOX21_ARE_BLA_agonist_viability", "TOX21_RT_HEPG2_GLO_40hr_viability", "TOX21_MMP_viability", "TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2_viability", "TOX21_p53_BLA_p3_viability", "TOX21_GR_BLA_Antagonist_viability", "ACEA_AR_antagonist_80hr", "TOX21_p53_BLA_p2_viability", "ACEA_AR_antagonist_AUC_viability", "TOX21_AR_BLA_Agonist_ratio", "TOX21_NFkB_BLA_agonist_viability", "TOX21_RT_HEPG2_FLO_08hr_viability", "TOX21_H2AX_HTRF_CHO_Agonist_ratio", "TOX21_AP1_BLA_Agonist_viability", "TOX21_p53_BLA_p1_viability", "TOX21_HDAC_Inhibition", "TOX21_ELG1_LUC_Agonist_viability", "TOX21_GR_BLA_Agonist_ratio", "ACEA_AR_agonist_AUC_viability", "TOX21_ERa_BLA_Agonist_ratio", "ACEA_ER_80hr", "TOX21_RAR_LUC_Agonist_viability", "TOX21_FXR_BLA_agonist_viability", "TOX21_ESRE_BLA_viability", "TOX21_TSHR_Agonist_ratio", "TOX21_p53_BLA_p5_viability", "TOX21_HSE_BLA_agonist_viability", "TOX21_AR_LUC_MDAKB2_Agonist", "OT_AR_ARSRC1_0960", "TOX21_RXR_BLA_Agonist_ratio", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist", "TOX21_HRE_BLA_Agonist_ratio", "TOX21_ERa_BLA_Antagonist_viability", "OT_FXR_FXRSRC1_0480", "TOX21_SBE_BLA_Agonist_viability", "TOX21_CASP3_HEPG2", "TOX21_RAR_LUC_Antagonist_viability", "TOX21_SBE_BLA_Antagonist_viability", "OT_ER_ERaERb_1440", "TOX21_PGC_ERR_Agonist", "OT_AR_ARSRC1_0480", "TOX21_TSHR_Antagonist_ratio", "OT_FXR_FXRSRC1_1440", "TOX21_ESRE_BLA_ratio", "TOX21_ERR_Agonist", "TOX21_RAR_LUC_Agonist", "OT_ER_ERaERb_0480", "OT_ER_ERbERb_1440", "TOX21_PPARg_BLA_Agonist_ratio", "OT_ER_ERbERb_0480", "OT_NURR1_NURR1RXRa_0480", "TOX21_PR_BLA_Agonist_ratio", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist", "OT_NURR1_NURR1RXRa_1440", "TOX21_HDAC_Inhibition_viability", "OT_ER_ERaERa_1440", "OT_ER_ERaERa_0480", "TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Agonist", "LTEA_HepaRG_LDH_cytotoxicity", "TOX21_CASP3_CHO", "TOX21_ERb_BLA_Agonist_ratio", "OT_AR_ARELUC_AG_1440", "UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist", "TOX21_NFkB_BLA_agonist_ratio", "TOX21_ELG1_LUC_Agonist", "ACEA_AR_agonist_80hr", "TOX21_SBE_BLA_Agonist_ratio", "TOX21_SSH_3T3_GLI3_Agonist", "OT_PPARg_PPARgSRC1_1440", "OT_PPARg_PPARgSRC1_0480"], "Assay_MOA": [null, "mayInformOn"], "ModeofAction": [null, "Thyroid Hormone - Thyroid Receptor Modulation", "Cancer - KCC8: Receptor Mediated Effects", null, "DART - Gene Expression", "Other Steroid Hormone - Progesterone Receptor Modulation", "DART - Progesterone Receptor Modulation", "AcuteTox - Cytotoxicity", "Cancer - KCC10: Cell Proliferation/Death/Energetics", "Estrogen - Estrogen-related Receptor Modulation", "DART - Estrogen-related Receptor Modulation", "DART - Other Developmental Signaling Transcription Factors", "DART - Androgen Receptor Modulation", "Androgen - Androgen Receptor Modulation", "Estrogen - Estrogen Receptor Modulation", "DART - Estrogen Receptor Modulation", "CardioTox - Endothelial Injury/Coagulation", "DART - Steroid Hormone Metabolism", "CardioTox - Cardiomyocyte/Myocardial Injury", "Other Steroid Hormone - Steroid Hormone Metabolism", "DART - Retinoic Acid Receptor Modulation", "Other Steroid Hormone - Glucocorticoid Receptor Modulation", "CardioTox - Change in Vasoactivity", "AcuteTox - p53 Signaling Pathway", "Cancer - KCC5: Oxidative Stress", "Cancer - KCC2: Genotoxic Effects", "DART - p53 Signaling Pathway", "DART - Aryl Hydrocarbon Receptor Modulation", "Cancer - KCC4: Epigenetic Alterations", "Thyroid Hormone - TSH Receptor Modulation", "Thyroid Hormone - Thyroid Hormone Metabolic Process", "DART - Thyroid Hormone Metabolic Process", "DART - Retinoid X Receptor Modulation", "Cancer - KCC6: Chronic Inflammation", "AcuteTox - Oxidative Stress", "DART - Oxidative Stress"], "MOA_ToxicityEndpoint": [null, "mayContributeTo"], "ToxicityEndpoint": [null, "Thyroid Hormone", "Cancer", "cHTS", "DART", "Other Steroid Hormone", "Acute Lethality", "Estrogen", "Androgen", "CardioTox"], "Assay_MechanisticTarget": [null, "throughMechanisticTarget"], "MechanisticTarget": [null, "Thyroid Receptor Modulation", "Progesterone Receptor Modulation", "Cell Viability", "Estrogen-related Receptor Modulation", "Other Developmental Signaling Transcription Factors", "Androgen Receptor Modulation", "Estrogen Receptor Modulation", "CardioTox_ER Alpha", "Aromatase Activity Modulation", "CardioTox_AroPro", "Other Transcription Factors", "Cell Cycle", "CardioTox_AP-1", "RAR-related Orphan Receptor Modulation", "Retinoic Acid Receptor Modulation", "Glucocorticoid Receptor Modulation", "CardioTox_NR3C1", "p53 Modulation", "CardioTox_TP53", "Constitutive Androstane\u00a0Receptor Modulation", "Aryl Hydrocarbon Receptor Modulation", "CardioTox_AHR", "Histone Modification", "TSH Receptor Modulation", "Retinoid X Receptor Modulation", "Oxidative Stress", "CardioTox_H1FA", "Farnesoid X-activated Receptor Modulation", "Apoptosis", "CardioTox_PPARG", "Peroxisome Proliferator Activated Receptor Modulation", "Not Annotated", "Inflammation", "CardioTox_NFKB", "DNA Damage"], "MT_NCIm_term": [null, "Thyroid Receptor Modulation", "Gene Expression Regulation, Thyroid Signaling", "Gene Expression Regulation, Steroid Hormone Nuclear Receptor", "Progesterone Metabolic Process", "Cell Viability Process", "Gene Expression Regulation, Other Transcription Factors", "Estrogen Metabolic Process", "Gene Expression Regulation, Developmental Signaling", "Androgen Metabolic Process", null, "Aromatase Activity", "Cell Cycle", "Glucocorticoid Metabolic Process", "p53 Signaling Pathway", "Gene Expression Regulation, Xenobiotic Response", "Histone Modification", "Thyroid-stimulating Hormone Receptor Activity", "Oxidative Stress", "Apoptosis", "Gene Expression Regulation, Fatty Acid Signaling", "Unannotated", "Inflammatory Response", "DNA Damage"], "MT_NCIm_term_ID": [null, null, "CUI:C2752610", "CUI:C1625136", "CUI:C1158333", "CUI:C1516362", "CUI:C1158342", "CUI:C1158330", "CUI:C1149069", "CUI:C0007586", "CUI:C1158343", "CUI:C2984306", "CUI:C1154743", "CUI:C1156199", "CUI:C1152778", "CUI:C0242606", "CUI:C0162638", "CUI:C1155266", "CUI:C0012860"]}